REVIEW ARTICLE

Insulin-like growth factor-binding protein-5 (IGFBP-5): a critical member of the IGF axis

James BEATTIE[1], Gordon J. ALLAN, Jennifer D. LOCHRIE and David J. FLINT

Hannah Research Institute, Ayr KA6 5HL, Scotland, U.K.

The six members of the insulin-like growth factor-binding protein family (IGFBP-1–6) are important components of the IGF (insulin-like growth factor) axis. In this capacity, they serve to regulate the activity of both IGF-I and -II polypeptide growth factors. The IGFBPs are able to enhance or inhibit the activity of IGFs in a cell- and tissue-specific manner. One of these proteins, IGFBP-5, also has an important role in controlling cell survival, differentiation and apoptosis. In this review, we report on the structural and functional features of the protein which are important for these effects. We also examine the regulation of IGFBP-5 expression and comment on its potential role in tumour biology, with special reference to work with breast cancer cells.

Key words: extracellular matrix (ECM), glycosaminoglycan, insulin-like growth factor-I (IGF-I), insulin-like growth factor-binding protein 5 (IGFBP-5), mammary gland, proteolysis.

INTRODUCTION

The IGF (insulin-like growth factor) axis plays a crucial role in regulating cellular growth, differentiation and apoptosis [1,2]. As such, these molecules are important in the development and regulation of many tissues. For example, the IGF axis is involved in controlling the growth, differentiation and regression of the mammary gland during cycles of pregnancy, lactation and post-lactational involution [3]. The IGF axis is also known to be involved in the differentiation and growth of embryonic tissues [4] and it may also play a role in the process of tumorigenesis under some specific circumstances [5].

The IGF axis itself consists of two peptide growth factors, IGF-I and IGF-II [6,7], cell-surface IGF-I and -II receptors (IGF-IR and IGF-IIR) [8,9], six well-characterized soluble IGF-binding proteins (IGFBP-1–6) [10–15] and a family of partially characterized IGFBP proteases [16] (Figure 1). IGF-I and IGF-II comprise 70 and 67 amino acid residues respectively and exert their effects through the IGF-IR and IGF-IIR, although the growth-promoting effects of IGF-II occur specifically through the IGF-IR [17]. As suggested by their nomenclature, the IGFs show structural and functional homology with insulin. In addition, the IGF-IR is a heterotetrameric receptor comprising two α and two β subunits ($\alpha_2\beta_2$) with homology with the IR (insulin receptor). On binding IGF-I, the IGF-IR displays intrinsic tyrosine kinase activity and activates intracellular signalling pathways that are similar to those described for the IR. The IGF-IIR is a large (approx. 280 kDa) single transmembrane protein with no homology with the IGF-IR or IR. The IGF-IIR is also known as the mannose 6-phosphate receptor. The signalling pathways activated by the IGF-IIR are not well defined.

The liver is the main source of circulating IGF-I, and expression of hepatic IGF-I is mainly under the control of pituitary GH (growth hormone) [18] and there is evidence for negative-feed-back regulation by IGF-I at the level of the pituitary to inhibit GH secretion [19]. Although this pattern of regulation is similar to the properties displayed by classical endocrine hormones, IGF-I and IGF-II (like IGF-IR and IGF-IIR) are expressed in a wide variety of cells and their expression is regulated in a cell- and tissue-type-dependent manner. For this reason, the IGFs are not viewed as classical endocrine hormones, but rather as paracrine or autocrine growth factors.

IGFBPs are important members of the IGF axis. Six of these binding proteins have been cloned (IGFBP-1–6) and they vary in length from 201 to 289 residues. After various post-translational modifications, their molecular size determined by gel electrophoresis falls in the range 24–44 kDa. By analogy to IGF-I and IGF-II, IGFBPs are also secreted by many cell types, and the profile of expressed IGFBPs is also regulated in a cell- and tissue-type-dependent manner. The IGFBPs bind IGFs with high affinity ($K_D \sim 0.1$ nM) and over 95 % of IGFs in serum and other biological fluids are bound to IGFBPs. As the affinity of IGFBPs for IGFs is higher than that of cell-surface IGF-IR ($K_D \sim 1$ nM), IGFs which are bound by soluble IGFBPs are restricted in accessing cell-surface IGF-IR. However, some IGFBPs can bind to ECM (extracellular matrix) GAGs (glycosaminoglycans) and other ECM proteins [20]. This reduces the affinity of the IGF–IGFBP interaction and has important consequences for the activity of both IGFs and IGFBPs. We discuss this phenomenon elsewhere in the review.

Other members of the IGF axis include a group of increasingly well-defined IGFBP proteases which act to hydrolyse IGFBPs.

Figure 1   The IGF axis consists of IGF-I and IGF-II polypeptides (orange), six IGFBPs (various colours), a family of IGFBP proteases (yellow) and cell-surface IGFBP receptor, IGF-IR and IGF-IIR (light grey)

Cell membrane receptors for IGFBP-1 and IGFBP-3 have been partially defined [211,212]. In the Figure, IGFBP-5 is shown interacting with components of the ECM at a site removed from the IGF-binding site. See text for further details.

By analogy to the interaction with ECM components, proteolysis of IGFBPs also results in a large reduction in affinity between IGFBPs and IGFs, and potentially releases the growth factors to interact with cell-surface receptors. In addition to these features, IGFBPs are reported to have IGF-independent effects in some tissues [21] and, consequently, these proteins should be viewed as more than a reservoir of tightly bound IGFs.

We focus on the structure and function of one of these IGFBPs, IGFBP-5. This IGFBP has been shown to display all the properties discussed above and is established as a key member of the IGF axis. We review the initial discovery of this protein, its molecular cloning, primary/secondary structure and post-translational modifications, with special reference to the effects of these modifications on the biological activity of IGFBP-5. The most important of these post-translational modifications, proteolysis, is highlighted. We report briefly on the limited three-dimensional structural information that is available for the protein. We also review the literature relating to the architecture of the *IGFBP-5* gene with special reference to regulation of mRNA expression through transcription factor-binding sites in the *IGFBP-5* promoter. In an extended section, we report in detail the interactions of IGFBP-5 with other biomolecules and the structure–function aspects of these interactions.

We discuss the activity of IGFBP-5 in relation to IGF-dependent and -independent actions and how these are affected by complexation with other biomolecules. We also highlight the pleiotropic nature of the protein with respect to enhancement or inhibition of IGF activity and its cell-context-dependent association with either growth-promoting, differentiation or apoptotic actions. Finally, we review the literature relating to the presence and activity of IGFBP-5 in various tumours. In this section, we emphasize recent work with breast cancer cells and tissues.

It is important the reader is aware that, as indicated above, IGFBP-5 is only one of a family of six IGFBPs. These proteins all bind IGF-I and IGF-II with high affinity and share other specific

properties. At appropriate locations within the review, we indicate where the activity of other IGFBPs may overlap with IGFBP-5 and deal briefly with such concepts as redundancy of function within the IGFBP family. For recent reviews on the structure and functional relationships within the whole IGFBP family, the reader is directed to two excellent reviews [22,23]. For a short review on some of the properties of IGFBP-5, see [24].

IGFBP-5: STRUCTURE

Primary structure

Cloning of mouse, rat, porcine and human *IGFBP-5* cDNAs [25–28] indicated a high degree of sequence conservation. The protein comprises 252 residues (28.5 kDa) and is expressed with a hydrophobic signal sequence (19–20 residues) that is characteristic of secreted proteins. It is a slightly basic protein (pI ~ 8.5). One of the most significant features of the primary sequence (along with the other IGFBPs) is the presence of a large number of highly conserved cysteine residues (Figure 2). There are 18 cysteine residues in IGFBP-5: 12 and six in the N- and C-terminal regions of the protein respectively. It has also been possible to partially assign disulphide bond linkages in the N- or C-terminal terminal domains of various IGFBPs [29–34] and for the entire IGFBP-6 protein [32] (Figure 3). These data indicated that the protein was completely disulphide-bonded within the N- and C-terminal regions of the protein, and this pattern of intra-domain disulphide bonding has led to a consensus model for IGFBP structure as comprising discrete N- and C-terminal domains joined by a 'hinge region' which has a less conserved and ordered structure. A report from Kalus et al. [31] indicates that Cys^{47} and Cys^{60} (C9 and C11) are disulphide-bonded, as are Cys^{54} and Cys^{80} (C10 and C12) (see Figure 3) to form the core of a 'mini-IGFBP-5' domain (see the next section). The assignment of these four N-terminal domain disulphide bonds was the same as that described for IGFBP-1, -3, -4 and -6 and has led to the suggestion

```
         *    *           *          *        *  **  *          *         *    *                              *
Rat IGFBP-1    APQPWHCAPCTAERLELCPPVP-AS-CPEISRPAGCGCCPTCALPLGAACGVATAACAQGLSCRALPGEPRPLHALTRGQGAC
Rat IGFBP-2    EVLFRCPPCTPERLAACGPPPDAP-CAELVREPGCGCCSVCARQEGEACGVYIPRCAQTLRCYPNPGSELPLKALVTGAGTC
Rat IGFBP-3    GAGAVGAGPVVRCEPCDARALAQCAPPPTAPACTELVREPGCGCCLTCALREGDACGVYTERCGTGLRCQPRPAEQYPLKALLNGRGFC
Rat IGFBP-4    DEAIRCPCSEEKLARCRPPVG---CEELVREPGCGCCATCALGLGMPCGVYTPRCGSGMRCYPPRGVEKPLRTLMHGQGVC
Rat IGFBP-5    LGSFVRCEPCDEKALSMC-PPSP-LGC-ELVKEPGCGCCMTCALAEGQSCGVYTERCAQGLRCLPRQDEEKPLHALLHGRGVC
```

```
(VLEPPPPATSSLSGSQHEEAKAAVASEDELAESPEMTEEQLLDSFHLMAPSREDQPILWNAISTYSSMRAREITDLKKWKE)
(EKRRVGATPQQVADSEDDHSEGGLVENHVDGTMNMLGGSSAGRKPPKSGMKELAVFREKVNEQHRQMGKGAKHLSLEEPKKLRPPPART)
(ANASAASNLSAYLPSQPSPGNTTESEEDHNAGSVESQVVPSTHRVTDSKFHPLHSKMEVIIKGQARDSQRYKVDYESQSTDTQNFSSESKRETEYG)
(TELSEIEAIQESLQTSDKDESEHPNNSFNPCSAHDHRCLQKHMAVRDRSKMKVVGTPREEPRPVPQG)
(LNEKSYGEQTKIERDSREHEEPTTSEMAEETYSPKVFRPKHTRISELKAEAVKKDRRKKLTQSKFVGGAENTAHPRVIPAPEMRQESDQG)
```

```
*                       *                               *                    *   *                  *
PCQRELYKVLERLAAAQQKA--GD-E-IYKFYLPNCNKNGFYHSKQCETSLDGEAGLCWCVYPWSGKKIPGSLETRGDPNCHQYFNVQN
PCQQELDQVLERISTMRLPDDRGPLEHLYSLHIPNCDKHGLYNLKQCKMSLNGQRGECWCVNPNTGKPIQGAPTIRGDPECHLFYNEQQENDGVHAQRVQ
PCRREMEDTLNHLKFLNVLSPRGV------HIPNCDKKGFYKKKQCRPSKGRKRGFCWCVDKYGQPLPGYDTKGKDDVHCLSVQSQ
SCQSELHRAILERLAASQ--S-RTH-EDLFIIPIPNCDRNGNFHPKQCHPALDGQRGKCWCVDRKTGVKLPGGLEPKGELDCHQLADSLQE
PCRRHMEASLQEFKASPRMVPRAV------YLPNCDRKGFYKRKQCKPSRGRKRGICWCVDKY-GMKLPGMEYVDGDFOCHAFDSSNVE
```

Figure 2   Sequence alignment of rat IGFBP-1–6

Asterisks indicate the location of 18 conserved cysteine residues clustered in the N- and C-terminal domains for each IGFBP. The two extra cysteine residues in IGFBP-4 are underlined. When a residue is identical in three out of five of the IGFBPs, it is shown in bold. Dashes have been introduced in the N- and C-terminal domains to allow for better alignment of sequences. The central domain of the IGFBPs show less conserved sequence and these residues are bracketed. Figure reproduced from [14] with permission. © 1991 The American Society for Biochemistry and Molecular Biology.

	N-terminal region	Central region	C-terminal region	Reference
hIGFBP-1	C1-C2-C3-C4-C5-C6-C7-C8-C9-C10-C11-C12 (5) (8) (16) (23) (32) (34) (35) (38) (46) (53) (59) (79)		C13-C14-C15-C16-C17-C18 (151) (181) (192) (203) (205) (226)	[32]
bIGFBP-2	C1-C2-C3-C4-C5-C6-C7-C8-C9-C10-C11-C12 (6) (9) (17) (35) (43) (45) (46) (49) (57) (64) (70) (90)		C13-C14-C15-C16-C17-C18 (186) (220) (231) (242) (244) (265)	[29]
rIGFBP-3	C1-C2-C3-C4-C5-C6-C7-C8-C9-C10-C11-C12 (13) (16) (24) (33) (42) (44) (45) (48) (56) (63) (69) (89)		C13-C14-C15-C16-C17-C18 (187) (214) (225) (236) (238) (259)	[30]
hIGFBP-4	C1-C2-C3-C4-C5-C6-C7-C8-C9-C10-C11-C12 (6) (9) (17) (23) (32) (34) (35) (38) (46) (53) (59) (79)	C13--C14 (110) (117)	C15-C16-C17-C18-C19-C20 (153) (183) (194) (205) (207) (228)	[34]
hIGFBP-5	C1-C2-C3-C4-C5-C6-C7-C8-C9-C10-C11-C12 (7) (10) (18) (25) (33) (35) (36) (39) (47) (54) (60) (80)		C13-C14-C15-C16-C17-C18 (172) (199) (210) (221) (223) (243)	[31]
hIGFBP-6	C1-C2-C3-C4--C5---------C6--C7-C8-C9-C10 (4) (7) (15) (19) (32) (38) (46) (53) (59) (79)		C11-C12-C13-C14-C15-C16 (138) (165) (176) (187) (189) (209)	[32]

Figure 3   Disulphide linkages in IGFBPs

Cysteine residues are numbered sequentially from the N-terminus. Numbers in parentheses represent the actual residue number (the first residue in the mature peptide is designated residue 1). r, rat; b, bovine; h, human. Reproduced from D. Byun, S. Mohan, D. J. Baylink and X. Qin (2001), Localization of the IGF binding domain and evaluation of the role of cysteine residues in IGF binding in IGF binding protein-4, J. Endocrinol., **169**, 135–143. © Society for Endocrinology (2001). Reproduced by permission.

that there are in fact two mini-domains within the N-terminus of IGFBP-5 (and by inference the other IGFBPs) with the core structure described by Kalus et al. [31] comprising the more C-terminal of these domains. Confirmation of this hypothesis, however, will require the full assignment of disulphide bonds within the N-terminal domain of IGFBP-5 and also a complete crystal structure for this region of the protein.

There are two other important regions of primary sequence within the IGFBP-5 protein. The first lies in the C-terminal domain where there is a consensus long (L) heparin-binding sequence (BBBXXB; B = basic amino acid; X = any amino acid). This region of the protein ($K^{206}RKQCK^{211}$), together with neighbouring basic residues, is important in binding ECM components and other proteins (see the 'Proteolysis' section below) [35]. There is also a region in the central domain of IGFBP-5 which contains a short (S) heparin-binding consensus sequence between residues 131 and 140 [36]. Deletion mutagenesis studies have indicated that this central domain may be cryptic in nature and may only be fully effective in the absence of the C-terminal heparin-binding region [37]. Following proteolytic cleavage of IGFBP-5, this central heparin-binding domain may become exposed and display specific biological properties. The central hinge region within IGFBP-5 is also the site of major post-translational modifications of the protein. Proteolysis within this domain is discussed in the next section, especially with reference to its effects on the affinity of IGFBP-5 for IGF-I; however, the central domain of IGFBP-5 is also believed to contain glycosylation sites, and IGFBP-5 was first reported as an O-glycosylated protein following its secretion from the U2 human osteosarcoma cell line [38]. The secretion of glycosylated IGFBP-5 from other cell types has been confirmed [39,40] and, subsequently, an IGFBP-5 fragment purified from haemofiltrate was shown to be glycosylated on Thr^{152}. The composition of the glycosyl moieties of IGFBP-5 has not been determined. It has been reported that glycosylation of some IGFBPs interferes with the ability of the proteins to bind to cell surfaces [41,42]. However, this has not been shown for IGFBP-5, and,

given the extensive interactions of this binding protein with other structures, this is a topic worthy of further investigation. The central domain of IGFBPs also contains potential phosphorylation sites. The serine phosphorylation of IGFBP-1 and IGFBP-3 within this domain has been clearly demonstrated [43,44], and this post-translational modification has been shown to affect the affinities of these IGFBPs for IGF-I and ECM constituents. However, there is only limited evidence for the phosphorylation of IGFBP-5 [45], and the nature and occurrence of phosphorylation in this particular binding protein needs further confirmation.

Secondary and tertiary structure

Although the *IGFBP-5* gene was cloned over 10 years ago [28], it is only recently that information relating to the three-dimensional structure of the protein has become available [31]. The crystallization of full-length IGFBPs has proven to be difficult. Such structural information that is available is derived from NMR or crystal structures of fragments or domains within the protein or has been inferred by homology modelling from partial structures of other IGFBPs. In 1998, Kalus et al. [31] reported the solution NMR structure of an N-terminal domain of IGFBP-5 comprising residues 40–92 termed 'mini-IGFBP-5' (see above). This domain was reported as a rigid globular structure having at its core three anti-parallel β-strands and containing two internal disulphide bonds (Cys^{47}–Cys^{60} and Cys^{54}–Cys^{80}). Although this mini-domain bound both IGF-I and IGF-II, affinities were reduced 10- and 80-fold respectively compared with wild-type. These reduced affinities of truncated proteins were mainly due to much higher dissociation rates for the complexes formed with IGFs. The authors described a hydrophobic patch on the surface of mini-IGFBP-5 lying outwith the anti-parallel β-strand core containing residues Val^{49}, Tyr^{50}, Pro^{62}, Lys^{68} and Leu^{75} which was important for binding IGF-II. Mutagenesis of five residues within this domain (Lys^{68}, Pro^{69}, Leu^{70}, Leu^{73} and Leu^{74}) to alter the hydrophobic properties of this region in the context of the full-length protein resulted in a 1000-fold decrease in affinity for IGF-I [46]. The mutant protein also had decreased ability to inhibit IGF-I biological action. One concern in such an extensive mutagenesis strategy is that the overall confirmation of the protein may be altered and that this, rather than specific residue substitution, may cause loss in recognition of ligand(s). The authors of this study indicated that the mutant protein was still susceptible to proteolysis following incubation with human fibroblast-conditioned medium, arguing that the overall conformation of the protein was not altered [46]. CD spectroscopic analysis of this mutant confirmed this finding [47].

Further NMR and crystallographic studies confirmed the molecular details of the interaction between mini-IGFBP-5 and IGF-II [31,48], and this group also used the crystallographic coordinates of the mini-IGFBP-5–IGF-II complex together with NMR studies to design low-molecular-mass inhibitors of the interaction between the two proteins [48]. Although the affinity of interaction between such compounds and mini-IGFBP-5 was only in the micromolar range, such an approach may ultimately yield pharmaceutically useful reagents. In a subsequent study [33], a mini-domain within NBP-4 [N-terminus of IGFBP-4 (residues 3–82)] was shown to have a global fold almost identical with that described for the mini-IGFBP-5 protein. These authors then described crystallization of the ternary complex NBP-4–IGF-I–CBP-4 [C-terminus of IGFBP-4 (residues 151–232)], although the definition of CBP-4 remained poor in this structure. Nonetheless, CBP-4 was reported to increase the affinity of NBP-4 for IGF-I 3–6-fold. Although there is no information of the structure of the C-terminal domain of IGFBP-5, there are some studies which

describe the structure of this domain in IGFBP-6 [49,50]. This binding protein (uniquely among the IGFBPs) demonstrates a 20–100-fold higher affinity for IGF-II compared with that for IGF-I [51], and it was suggested that the differential affinity displayed towards the growth factors may be attributed to residues within this C-terminal domain [50]. Caution must therefore be exercised when extrapolating from studies that examine structural elements within the C-terminal domain of IGFBP-6 and the same domain in other IGFBPs. Nevertheless, using a construct containing 27 residues of unstructured vector sequence followed by 80 residues from the C-terminal domain of IGFBP-6 (residues 161–240), Headey et al. [50] describe a structure analogous to a thyroglobulin type-1 fold with an initial α-helix connected by a loop to a three-stranded antiparallel β-sheet structure leading finally to a flexible disulphide-bonded second loop. NMR studies, together with site-directed mutagenesis, identified residues within this C-terminal domain that are important for interaction with IGF-II and indicate that this ligand-binding site is in close proximity to a positively charged sequence located within the first β-turn and β-bulge of the central β-sheet structure. This may provide a rationale for the reduction in affinity of IGFBPs for IGFs following the binding of the former proteins to ECM structures [50], a phenomenon widely reported for IGFBP-5. Further studies from this group using NMR techniques suggested some conformational changes involving these residues within the C-terminal domain of IGFBP-6 following IGF-II binding.

Recent papers have also reported the structures or properties of the C-terminal domains of IGFBP-1 and -4 [33,49,52,53]. The crystallization of a C-terminal fragment of IGFBP-1, isolated and purified from amniotic fluid, has also been reported [49]. This domain also demonstrated a thyroglobulin type-I fold, although the length of the α-helix in the IGFBP-1 structure is longer (19 residues) than that of the IGFBP-6 structure (15 residues). In addition, both the length of anti-parallel β-strands and the exact positioning of loops connecting elements of secondary structure vary between IGFBP-1 and IGFBP-6 C-terminal domain structures. A C-terminal fragment (residues 136–237) of IGFBP-4 has been purified from human haemofiltrate and has been produced recombinantly [52]. Although only limited information was provided from a crystal structure of this fragment, ^{1}H-NMR spectroscopy suggested the predominance of α-helical components in this region.

In summary, there is no crystal or solution structure available for any full-length IGFBP. For IGFBP-5, limited structural information is available for an important IGF-binding region within the N-terminal domain of the protein. In recent years, some structural information has begun to appear in respect of the C-terminal domains of IGFBPs -1, -4 and -6. Given the high degree of homology between the IGFBP families, it could reasonably be expected that the structures described for the C-terminal domains for these IGFBPs may be represented to some extent in the IGFBP-5 C-terminal domain. However, confirmation of this observation requires further experimentation. Given the amount of interactions with other biomolecules which this region displays, such structural information is of paramount importance for the molecular dissection of these binding events.

IGFBP-5 GENE STRUCTURE AND PROMOTER REGULATION

Cloning of the rat and mouse *IGFBP-5* genes [26,28] indicated that they both spanned some 17 kb and comprised four exons and three introns. The size of the gene was largely determined by the size of the first intron (10 kb) located between exons and 1 and 2. For the rat gene, a transcriptional start site was identified 772 nucleotides 5′ of an ATG translation initiation codon. The

mouse *IGFBP-5* gene is present on chromosome 1, where it is separated from the *IGFBP-2* gene by only 5 kb and is arranged in a 'tail-to-tail' orientation with respect to that gene. Cloning of the human *IGFBP-5* gene [25] revealed a similar organization to that described for the rodent genes. With a first intron of 25 kb and a total gene size of 33 kb, the human gene was somewhat larger than the rodent counterpart. However, as found for the mouse, the human *IGFBP-5* gene was closely linked to the *IGFBP-2* gene and was arranged in the same orientation with respect to that gene. A transcription initiation site was identified in a similar location to that of the rat gene, and limited promoter analysis indicated that 461 bp of sequence upstream from the mRNA cap site directed the expression of a CAT (chloramphenicol acetyltransferase) construct transfected into the MDA-MB-468 human breast cancer cell line. Subsequently, Rotwein and colleagues used deletion analysis of *IGFBP-5* promoter–luciferase constructs transiently transfected into the differentiating mouse C2 myoblast cell line to show that 156 nt of 5′ flanking DNA sequence from the *IGFBP-5* promoter retained 70 % of the activity of a 1004 bp luciferase construct [54]. Further studies indicated that the same region of the mouse gene was active in transient transfection experiments in the human Hep G2 liver cell line and that a region at -70 to -34, which is footprinted with Hep G2 nuclear extracts, was responsible for the majority of this activity [54]. Further work involving co-transfection of human *IGFBP-5* promoter–luciferase constructs and AP-2 (activator protein 2) constructs into a human dermal fibroblast cell line indicated up-regulated expression of the luciferase constructs by this transcription factor and identified regions at -152 to -127 and -57 to -30 as being important for binding AP-2 and conferring cAMP-responsiveness to the *IGFBP-5* gene [55]. Following this work, a series of studies examined the regulation of IGFBP-5 expression in foetal rat osteoblasts [56–60]. McCarthy et al. [56] reported that AP-2 may be important in conferring PGE_2 (prostaglandin E_2) sensitivity on the *IGFBP-5* promoter, although these PGE_2-responsive elements were later reported to be further upstream (in regions at -2695 to -1470 and -989 to -332) than found previously [57]. These authors confirmed that the *IGFBP-5* promoter in rat foetal osteoblasts was also sensitive to cAMP [57], confirming the findings reported for dermal fibroblasts [55]. Using deletion and point mutant analysis of the *IGFBP-5* promoter in rat foetal osteoblasts, Gabbitas et al. [57] found that a region between -70 and $+22$ was required for basal promoter activity along with cortisol sensitivity and that this area also contained a putative E-box/c-Myb-binding motif. In an extensive study using similarly mutated *IGFBP-5* promoter constructs, it was established that mutations in the E-box decreased basal promoter activity and also eliminated the stimulatory effect of PGE_2 on luciferase expression [59]. The same study reported putative binding sites for the transcription factors C/EBP (CCAAT/enhancer-binding protein) and NF-1 (nuclear factor-1), and mutations in either of these elements reduced promoter activity. However, a very recent study with the human neuroblastoma cell line LAN-5 showed that mutation of CCAAT/ enhancer element in a -83 to $+53$ *IGFBP-5* promoter–luciferase construct increased the transcription of the transiently transfected plasmid [61]. These contradictory results may reflect cell-specific effects.

Studies using foetal rat osteoblast cultures have also indicated negative *cis*-acting regions in the *IGFBP-5* promoter. For example, an inhibitory effect of OP-1 (osteogenic protein-1) was reported, and the location of this OP-1 inhibitory site was reported to be in the E-box/c-Myb-binding region described above [58,60]. In primary cultures of human osteoblasts and in a human osteoblast cell line, progesterone-responsive elements associated with a repeated CACCC box motif lying within the region -162 to

-124 were identified. Thus, following co-transfection of the progesterone receptor-A isoform and *IGFBP-5* proximal promoter– CAT constructs, progesterone treatment of cells results in an increase in CAT expression [62].

The other cell culture model used extensively to investigate the regulation of the *IGFBP-5* promoter are mouse and human neuroblastoma cell lines [61,63]. Tanno et al. [63] reported two Myb-binding sites at -429 to -424 and -59 to -54. This latter site may correspond to the E-box/c-Myb site reported previously in foetal rat osteoblasts. This group also reported that the more distal site was important for Myb-directed stimulation of the *IGFBP-5* promoter, although they found Myb stimulation of IGFBP-5 expression independently of binding to transactivation domains [63]. In addition, this study demonstrated an Akt-responsive element between -334 and -83 [63]. This may be of significance as IGF-I is known to activate the serine/threonine kinase Akt in a phosphoinositide 3-kinase-dependent manner to up-regulate *IGFBP-5* expression [64]. Also using neuroblastoma cell lines, an RA (retinoic acid)-responsive element involving a CACCC tandem repeat lying between -147 and -137 was described, and this same element may contribute to RA-induced up-regulation of IGFBP-5 expression in rat osteoblasts [65], although it should be noted that RA is reported to decrease IGFBP-5 expression in other cell lines and primary culture systems [66,67]. Clearly, further studies are required to define the precise role of RA in the regulation of IGFBP-5 expression. It should be recalled that, in osteoblast-like cells, this motif was also described as constituting a progesterone-responsive element. Unlike those with osteoblast cells, studies with neuroblastoma cells indicated that the C/EBP-responsive element had a repressive effect on *IGFBP-5* transcription [61]. Clearly there are cell-specific factors that are important in the regulation of IGFBP-5 expression, and further work is required to identify such factors that are involved in the control of *IGFBP-5* gene expression, especially during growth, differentiation and apoptosis in different cell types. A summary of known transcription factor binding sites on the *IGFBP-5* promoter is shown in Figure 4.

IGFBP-5 PROTEOLYSIS

The earliest reports of IGFBP proteolysis describe an activity in late human pregnancy serum directed against IGFBP-3 [68,69]. Shortly thereafter this proteolytic activity was confirmed in pregnant mouse and rat serum [70,71], in human amniotic fluid and in seminal plasma [72,73]. The first report of proteolytic activity directed towards IGFBP-5 was described in conditioned medium from human fibroblast cultures [74], and this report also described the inhibition of IGFBP-5 proteolysis by pre-complexation of binding protein with IGF-I. This finding was confirmed as IGFBP-5 proteolytic activity and was subsequently identified and partially characterized in conditioned medium of cultures of the U-2 human osteosarcoma cell line [75,76], from cultures of follicle-stimulating hormone-stimulated rat granulosa cells [77] and in the T47D human breast carcinoma cell line [78]. IGFBP-5 derived from primary cultures of human dermal fibroblasts was also protected from proteolysis by pre-complexation with ECM components including heparin and heparan sulphate [79]. The presence of O-sulphate groups at positions 2 and 3 of the uronic acid monomer units of these GAGs was critical for this activity. Initial attempts at further characterization of the IGFBP-5 proteolytic activity secreted by human fibroblasts described a Ca^{2+}-dependent serine protease which cleaved IGFBP-5 into non-IGF binding fragments of 22, 20 and 17 kDa. Subsequently, the same workers reported a molecular mass of 92 kDa for this serine protease, but also described a metalloprotease activity (or

Figure 4   Location of putative transcription-factor-binding sites within the proximal promoter region of IGFBP-5, identified relative to the mRNA CAP site ($+1$)

Agents shown to regulate IGFBP-5 expression are indicated in parentheses below transcription factors. With the exception of OP-1, these act to increase IGFBP-5 expression. PGE$_2$-RE, PGE$_2$-responsive element.

activities) in the molecular mass range 55–72 kDa secreted by human fibroblasts [19]. In these experiments, the serine protease was always the more active towards IGFBP-5. Confirmation of both serine protease and metalloprotease activity directed towards IGFBP-5 was then reported in conditioned medium from mouse osteoblast and neuroblastoma cell lines [80,81] and also in primary cultures of ovine articular chondrocytes [82].

Following these general descriptive studies of IGFBP-5 protease activity in different cell culture systems, researchers began to identify specific IGFBP-5 proteases. It had already been demonstrated that plasmin [83] and thrombin [84] acted to cleave IGFBP-5, and, subsequently, proteolysis of IGFBP-5 by the serine proteases cathepsin G and elastase was also described [85]. In 2000, an important paper [86] described the cloning and characterization of ADAM-12s (a disintegrin and metalloprotease 12 short-form) which is active on IGFBP-5, and Mohan and colleagues subsequently described the secretion of another member of this family (ADAM-9) by human osteoblast cultures [87]. At about the same time, the main serine protease secreted by human fibroblasts was identified as C1s, a member of the complement proteolytic cascade [88]. More recently, two groups have described the proteolysis of IGFBP-5 by PAPPs (pregnancy-associated plasma proteases) A and A2, which are present in several different biological fluids [89–91]. These proteases belong to the class of Zn^{2+}-dependent metalloproteases and appear to cleave IGFBP-5 specifically between Ser[143] and Lys[144]. As for the serine proteases, the activity of PAPP-A and PAPP-A2 is inhibited in the presence of IGF-I. A variant of PAPP-A, PAPP-Ai, which contains a highly basic 29-residue insert has been cloned and was shown to have proteolytic activity towards IGFBP-5 [92]. Most recently, a novel serine protease has been identified after being expressed in insect cells and purified to homogeneity from the growth medium [93]. Intriguingly, the protein has a region of sequence identity with the N-terminal 90-amino-acid sequence in the IGFBP family itself. Northern blotting analysis indicated a widespread expression pattern for this protease, with particularly high levels in uterus and placenta [93]. Further details as to the nature of this protease are awaited with interest.

The observation that IGFBP-5 is protected from proteolysis by engagement with IGF-I, heparin and other molecular components of the ECM, together with reports of biological activity of IGFBP-5 proteolytic fragments themselves, argues for the importance of the IGFBP-5 proteolytic axis in regulating the biological activity

of the binding protein and also of IGF-I, IGF-II and ECM in controlling this process. The fact that the affinity of IGFBP-5 (and other IGFBPs) for IGF-I is greater than that of the IGF-IR led to the emergence of a paradigm that IGFBP proteolysis was required for the release of hormone from binding protein in order to allow subsequent binding to receptor and manifestation of IGF-I action. However, there is a literature which describes effects of unliganded intact IGFBP-5 and also activities associated with IGFBP-5 fragments. This is a controversial area, with several contradictory findings reported. For example, an early study found that a 22 kDa fragment of IGFBP-5 did not enhance the proliferative response of human foetal fibroblasts (plated on to ECM derived from the same cells or on to placental Type IV collagen) to added IGF-I, whereas the intact IGFBP-5 protein (100 ng/ml) appeared to enhance the proliferative response to IGF-I (20 ng/ml) by up to 100 % [94]. The same inference of ablation of IGFBP-5-enhancing activity following proteolysis has been drawn in studies using protease-resistant forms of IGFBP-5 [95]. This study used pSMC (porcine smooth-muscle cell) cultures to demonstrate that a protease-resistant form of IGFBP-5 (but not the wild-type protein) inhibited IGF-I stimulation of protein and DNA synthesis and also inhibited IGF-I-induced cell migration in these cultures [95]. The conclusion drawn from these studies was that an endogenous proteolytic activity secreted by the cells inactivated wild-type IGFBP-5, but was unable to act on the protease-resistant molecule, resulting in differential inhibitory activities displayed by these proteins [95]. Indeed, these authors confirmed that protease-resistant IGFBP-5 was stable for up to 24 h in culture with these cells [95]. In a similar fashion, studies in cultures of rat growth-plate chondrocytes demonstrated that both N-terminal (residues 1–169) and C-terminal (residues 144–252) fragments of IGFBP-5 had no effect on IGF-I-stimulated cell proliferation, whereas the intact protein again increased IGF-I activity by up to 100 % [96]. Intact IGFBP-5 was also reported to stimulate growth of primary cultures of human intestinal smooth-muscle cells via activation of the MAPK (mitogen-activated protein kinase) and ERK1/2 (extracellular-signal-regulated kinase 1/2) signalling pathways [97].

These early studies mainly focused on the effects that proteolysis of IGFBP-5 would have on IGF-I action and not on the possible IGF-independent effects of IGFBP-5 and its proteolytic fragments. However, working with neonatal mouse osteoblasts, Andress [98] and Andress and colleagues [99] demonstrated

that IGFBP-5 fragments 1–169 and 201–218 (as well as intact IGFBP-5) caused serine phosphorylation of a 420 kDa putative IGFBP-5 receptor protein derived from cell membrane extracts. To date, this putative IGFBP-5 receptor protein has not been cloned or characterized further. A direct effect of IGFBP-5 fragment 201–218 in stimulating $^{35}SO_4^{2-}$ uptake into cultures of bovine vascular epithelial cells has been reported [100], although the EC_{50} for this effect (2 μM) is somewhat high. This same peptide also caused a direct change in phenotype when added to cultures of mesangial cells derived from rat glomerulus which was associated with filopodia formation and a rapid re-organization of the actin cytoskeleton [101]. The fragment 201–218 of IGFBP-5 has also been reported to displace intact binding protein from ECM structures [102] and therefore may have indirect effects through this mechanism. The area 201–218 in the C-terminal domain of the protein has been the subject of intense study (see below). Although proteolysis of IGFBPs has been commonly reported to generate non-IGF-binding fragments of the protein, there is some limited evidence that fragments of the binding protein may retain a reduced affinity for IGF-I [103], although the physiological significance of this observation has not been studied in any detail. IGFBP-5 fragments were reported to enhance mitogenesis in rat osteoblasts cells; however, recent studies using transgenic mice expressing IGFBP-5 fragments 1–162 and 1–193 under the control of an osteocalcin promoter showed no obvious changes in skeletal phenotype [104]. In contrast, transgenic mice expressing full-length IGFBP-5 from an osteocalcin promoter show decreases in bone trabecular volume, ECM/mineral ratios and osteoblast function [105,106]. Overexpression of IGFBP-5 in the osteoblastic cell line MC3T3-E1 also delayed or decreased the appearance of mRNA for bone-formation markers (e.g. osteocalcin and osteopontin) and inhibited the formation of bone nodules in confluent cell cultures [107]. Subsequent reports in IGFBP-5-overexpressing mice indicated that this bone phenotype was restricted to male mice and that IGFBP-5 transgenic animals also demonstrated increased neonatal mortality, growth inhibition and reduced muscle development, although, in these studies, IGFBP-5 expression was expressed ubiquitously from a CMV (cytomegalovirus) enhancer/β-actin promoter construct [108,109]. It would be interesting to test further the hypothesis that IGFBP-5 fragments have direct biological activity through transgenic routes such as these. Inhibition of IGFBP-5 proteolysis may have important biological and clinical implications. In an experimental model of osteoarthritis in dogs, it was shown that inhibition of the IGFBP-5 protease C1s in joint fluid increased the concentration of intact IGFBP-5 and IGF-I in the joint space [110]. This in turn was associated with an improvement in the structure of the joint during the development of osteoarthritis [110]. However, further studies have shown that IGFBP-5 (and other IGFBPs) are increased in chondrocytes and bone matrix during arthritic joint deterioration [39,111,112]. A positive correlation was reported between histological markers of joint pathology and IGFBP levels [111], and it was suggested that elevated IGFBPs sequestered IGFs, thus aiding the process of joint damage [39]. A review of the occurrence and physiological significance of IGFBP proteolysis has been published [113].

IGFBP-5: INTERACTIONS WITH ECM AND OTHER PROTEINS

Elsewhere in this review, we have indicated that IGFBP-5 binds to protein and GAG components of the ECM. In this section, we report in more detail on this phenomenon, on the structural elements within IGFBP-5 important for binding to ECM components and on the biological consequences of this interaction.

The first indication that IGFBPs interacted with biomolecules other than IGFs came with the observation that gel chromatography of heparinized plasma in a heparin-containing buffer caused a 70–80 % shift in immunoreactive IGF from a high-molecular-mass complex (140 kDa) to an elution position characteristic of free IGF [114]. Following this initial study, later work by the same group using immunoblotting and immunohistochemical techniques identified IGFBP-5 associated with ECM preparations derived from human foetal fibroblasts [94]. This group demonstrated direct binding between IGFBP-5 and individual components of the ECM (Type III and IV collagen, laminin and fibronectin). A key finding in this study was that IGFBP-5 enhanced the growth response of human fibroblasts (plated on either ECM or Type IV collagen) to added IGF-I. IGFBP-5 has also been reported to bind to osteoblast and osteoclast-like cells [98], although, in this instance, no binding was observed to the ECM derived from these cells. However, a later study identified that IGFBP-5 associates with ECM derived from cultured mouse calvariae [115], and IGFBP-5 has also been described in ECM derived from human chondrocyte cultures and ECM derived from the clonal mouse osteoblastic cell line MC3T3-E1 [21,39], in ECM from primary cultures of rat osteoblast and periosteal cells [116], in membranes derived from ovine and bovine granulosa cell cultures [117,118] and in a canine mammary tumour cell line [119]. The overwhelming consensus is that IGFBP-5 is able to associate with ECM components and also with cell membrane structures derived from several different tissues, and a previous report has described a methodology for quantifying the amount of IGFBPs associated with ECM components [120].

Several studies have subsequently examined the biological significance of IGFBP-5–ECM association. Abrass et al. [121] have shown that both intact IGFBP-5 and also the heparin-binding domain defined between residues 201–218 are able to stimulate directly the migration of mesangial cells, and other studies have reported that ECM competes with cell membrane structures for binding to IGFBP-5 [122]. These studies also suggested that the enhancing activity of IGFBP-5 (with respect to IGF-I) was associated with a reduction in affinity between IGFBP-5 and IGF-I when the former was bound to the ECM. This may be physiologically relevant, as the affinity of soluble IGFBP-5 for IGF-I is an order of magnitude greater than that of the IGF-IR (see the Introduction). The reduction in affinity of IGFBP-5 for IGF-I when the former is bound to ECM suggested that this may provide a low-affinity 'sink' for IGFs, leading to release of growth factor to neighbouring IGF-IRs due to favourable kinetic and equilibrium binding constants that exist between IGFs, IGFBP-5 and IGF-IR under these circumstances. Although this is a view that has a large degree of support in the literature, recent work from our group [123] using biosensor technology has questioned this assumption (see below).

Arai et al. [79] reported that IGFBP-5 also bound to the GAGs heparan sulphate and dermatan sulphate and to other anionic polysaccharides, such as dextran sulphate, which share the structural motif of O-sulphation at positions at C-2 or C-3 of glucose monomers, similar to the O-sulphation present at these positions in the iduronic acid moiety of GAGs which bind IGFBP-5. Importantly, heparin was able to inhibit the interaction between IGF-I and IGFBP-5 and could separate preformed complexes of growth factor and binding protein [79]. This study indicated that a synthetic peptide spanning the region 201–218 inhibited the effect of heparin in disrupting IGF-I–IGFBP-5 interactions, providing further evidence that this region in the IGFBP-5 protein may be responsible for binding to GAGs [79]. As indicated by these authors, this peptide contains the motif (see the section on structure above) characteristic of a long (L) heparin-binding domain

[79], and sequence analysis indicates that heparin-binding consensus sequences exist in all IGFBPs (with the exception of IGFBP-4) [14,35]. Although the majority of studies have focused on the effect of ECM/heparin binding on the biology of IGFBP-5 (and the closely related IGFBP-3), other IGFBPs interact with ECM components. For example, IGFBP-2 interacts with heparin if it is first pre-complexed with IGF-I [124]. For this binding protein, a different paradigm therefore exists for interaction with heparin and possibly other ECM components. We have confirmed these results using biosensor technology (J. Beattie and K. Phillips, unpublished work), and we believe that these findings for IGFBP-2 warrant further investigation.

IGFBP-5 has been reported to bind to other ECM proteins. Using co-immunoprecipitation techniques, Nam et al. [124a] demonstrated that IGFBP-5 bound to TSP-1 (thrombospondin-1) and OPN (osteopontin). The affinity of binding to these protein constituents of the ECM was in the low-nanomolar range (similar to the affinity of heparin binding). Other GAGs were able to disrupt the binding of IGFBP-5 and TSP-1/OPN, although the pattern of inhibition was somewhat complex. The 201–218 peptide fragment from IGFBP-5 was able to disrupt the interaction of IGFBP-5 with these ECM molecules, and a mutagenesis strategy within this region of IGFBP-5 suggested that residues Arg[201] and Arg[214] were the most important for binding TSP-1 and that Arg[214], Lys[217] and Arg[218] were critical for interaction with OPN. Interestingly, and in contrast with the situation with heparin, binding of IGFBP-5 with either TSP-1 or OPN did not reduce the affinity of IGFBP-5 for IGF-I. In this study, the growth response of primary cultures of pSMCs to IGF-I was enhanced by the simultaneous addition of IGFBP-5. If the cells were grown on a matrix of TSP-1 or OPN, the enhancing effect of IGFBP-5 was augmented further. A recent study, however, indicated that if IGFBP-5 was added to pSMC cultures which had already been exposed to IGF-I and TSP-1, protein synthesis and cell migration were inhibited [125]. In this instance, it was shown that IGFBP-5 inhibited the interaction between TSP-1 and integrin-associated protein. At a signalling level, this prevented the enhancement of IGF-IR tyrosine phosphorylation and MAPK activity in response to IGF-I. Further investigations indicated that such an effect was due to the delay in the transfer of the tyrosine phosphatase SHP-2 (Src homology 2 domain-containing tyrosine phosphatase) to the IGF-IR, which in turn prolonged the IGF-IR tyrosine phosphorylation response. It would appear therefore that an inhibitory or enhancing response by IGFBP-5 can be dependent on whether cells are pre-incubated with the binding protein or potential binders of IGFBP-5 or whether experiments are performed using simultaneous or sequential addition of test substances. This means that data obtained in such experiments must be interpreted carefully and that careful attention to experimental design is required under these conditions.

It has been indicated that IGFBP-5 also bound to the ECM protein VN (vitronectin) [126]. As for TSP-1 and OPN, binding affinity of IGFBP-5 for VN was in the low-nanomolar range, and the interaction of the binding protein with VN did not affect the affinity for IGF-I. The region 201–218 of IGFBP-5 was also determined to be important in VN binding, and a mutational analysis suggested that the ability of IGFBP-5 to enhance IGF-I stimulation of smooth-muscle-cell migration in the presence of VN was dependent on its ability to bind both VN and IGF-I simultaneously. A non-IGF-binding mutant of IGFBP-5 had no effect in enhancing the cellular response to IGF-I, in contrast with other reports which indicated IGF-independent effects of ECM associated IGFBP-5 [99,127–129]. The interaction of IGFBP-5 with VN differs from that with other ECM components in that residues 131–141, lying within the central domain of IGFBP-5,

are also involved in binding VN. In this respect, this binding interaction resembles that between an acid-labile subunit and IGFBP-5 [130]. It therefore appears that differences exist between the binding sites on IGFBP-5 for different ECM components and that this may effect the ability of IGFBP-5 to enhance or inhibit IGF-I action. Independent confirmation of the association of IGFBP-5 with VN has been reported [131], along with confirmation that tripartite complexes of VN–IGFBP-5–IGF-I are required to demonstrate IGFBP-5 enhancement of IGF-I-stimulated migration of the human breast cancer cell line MCF-7 when cells are grown on a substratum of VN. Recently, it has also been demonstrated that VN–IGFBP-5–IGF-I complexes can enhance protein synthesis and cell migration in human keratinocytes [132]. Many ECM proteins (including TSP-1, OPN and VN) bind to the integrin $\alpha V\beta 3$, and there is evidence that this receptor must be occupied to allow cells to respond to IGF-I [133]. There are also studies *in vitro* and *in vivo* which use small non-peptide inhibitors of ligand binding to $\alpha V\beta 3$ that inhibit IGF-I-stimulated DNA synthesis and migration of smooth-muscle cells [134]. This phenomenon is associated with hypophosphorylation of IGF-IR, and an attenuation of IGF-I-induced IGFBP-5 synthesis is also evident.

IGFBP-5 has also been reported to bind the ECM protein PAI-1 (plasminogen activator inhibitor-1) [135]. This protein plays an important role in regulating protease activity during ECM remodelling. The protein was identified following affinity chromatography of human fibroblast-conditioned medium on an Affigel column containing immobilized peptide 201–218 from IGFBP-5. Confirmation of binding to IGFBP-5 was obtained by co-immunoprecipitation studies using purified proteins. A mutagenic analysis of the interacting region of IGFBP-5 with PAI-1 indicated a 71 % decrease in binding of the mutant R201A/K202N/K206N/K208N. This same mutant showed only minimally reduced GAG binding [136], indicating, once again, subtle differences in the nature of the binding sites on IGFBP-5 for ECM components. As for TSP-1, VN and OPN, PAI-1 complexation with IGFBP-5 did not affect the affinity of the latter molecule for IGF-I. The K_D of PAI-1 for IGFBP-5 itself was reported at 90 nM, which is less than that of other ECM protein interactions with IGFBP-5. PAI-1 is a constituent of ECM preparations isolated from cultures of fibroblasts and is also produced by smooth-muscle cells, where it has an important role in regulating plasminogen activation and can control processes such as wound repair and ECM remodelling. IGFBP-5 has been shown to inhibit the activity of PAI-1 in an IGF-independent manner [135,137], causing an increase in plasmin activity, which in turn may have important consequences for the processes of wound repair and tissue remodelling.

The kinetics and affinities of complex formation between biomolecules plays an important role in the biological activities of such complexes. In recent years, the technique of SPR (surface plasmon resonance) has been used to examine the kinetics and affinities of interaction between different biomolecules [52,138,139]. This technology, in which one partner of a binding pair is immobilized (usually covalently) on to the surface of a biosensor chip while a solution of interacting partner is passed across the chip surface has been used to probe the kinetics and affinities of interaction between intact and fragmented IGFBPs and IGF polypeptides [50,123,140,141] and has provided useful information on those regions within the IGFBPs which are important for binding IGF-I and IGF-II. We have discussed above the interaction of IGFBP-5 with various components of the ECM, and, in an attempt to gain more insight into the nature of these interactions, we have used the technique of SPR to probe these events in more detail. We have carried out an extensive analysis of the interaction of IGFBP-5 with immobilized IGF-I, heparin,

Figure 5   Biosensor analysis of WT, AA–EA and IGF⁻ mutant IGFBP-5 binding to immobilized IGF-I, heparin, PAI-1 or tPA

Details of mutant proteins are described in [123] and biosensor methodology is described in detail in [141a]. The IGF⁻ mutant protein was originally described by Imai et al. [46] and shows no detectable binding to IGF-I, but has unimpaired binding to heparin, PAI-1 and tPA.

PAI-1 and tPA (tissue plasminogen activator) surfaces. Such data are reported in the form of sensorgrams (Figure 5) which profile in real time the association of analyte (IGFBP-5) with immobilized ligand (IGF-I, heparin, PAI-1 and tPA respectively). Examination of the binding profiles allows both quantitative and qualitative information to be derived in relation to rate constants (K_a and K_d) and equilibrium constants (K_D). For IGF-I, the K_D for IGFBP-5 (derived as K_d/K_a) is approx. 0.2 nM, which agrees very closely with the values derived previously using solution-phase equilibrium-based binding methods. Inspection of the binding curves for the IGF-I–IGFBP-5 interaction suggest that the high binding affinity seen for this interaction is largely the result of the slow dissociation rate of the IGF-I–IGFBP-5 complex. For the interaction of IGFBP-5 with heparin, PAI-1 or tPA, it is clear that the binding complexes in each instance show a much more rapid dissociation than for the IGF-I–IGFBP-5 complex. Under these conditions, the binding complex reaches equilibrium more rapidly (plateau region on sensorgrams), and the equilibrium constant K_D can be derived from a standard binding isotherm plot of analyte concentration against equilibrium response. This method indicates that the affinity of these ECM components for IGFBP-5 is ∼ 10–100-fold lower than for the IGF-I–IGFBP-5 complex and agrees with previous reports where these affinities have usually been determined by solution equilibrium-based methods [124a,126]. Together with the observation that the faster dissociation of these complexes leads to a more dynamic molecular interaction, these data can inform on the distribution of IGFBP-5 between IGF-I and ECM components. In relation to heparin, we have demonstrated that binding of this GAG and IGF-I to IGFBP-5 is mutually exclusive and that tripartite complexes of IGF-I–IGFBP-5-heparin do not form [141a]. We postulated therefore that free IGF-I may displace IGFBP-5 which is pre-bound to ECM structures, and indeed previous studies had demonstrated that addition of IGF-I to cultures of human fibroblasts was able to displace IGFBP-3 into the medium presumably from its location in ECM or cell membrane components [75,142]. We have shown subsequently the same effect for IGFBP-5 when IGF-I is added to monolayer cultures of the mouse mammary epithelial cell line HC11 [141a]. To investigate further the relationship between IGF-I and heparin-binding sites, an extensive series of mutagenesis studies have been undertaken [37,47,123,143–145]. Initially, it was shown that individual mutation of two highly conserved residues Gly[203] and Gln[209] within the 201–218 C-terminal heparin-binding domain of IGFBP-5 caused a 6–8-fold decrease in affinity for IGF-I and combined mutagenesis of these two residues resulted in a 10–30-fold reduction in affinity [47,144]. Although the Gly[203] and Gln[209] mutants did not show a decrease in heparin binding, a protein containing mutants in the same location, namely R201L/K202E/K206Q/R214A, had greatly reduced heparin binding [145]. This led the authors to suggest that the IGF-I- and heparin-binding sites on IGFBP-5 may overlap and provided a rationale for the failure to observe tripartite complexes of IGF-I–IGFBP-5–heparin in biosensor studies and also for the ability of IGF-I to displace heparin from preformed complexes of IGFBP-5–heparin and also to release IGFBP-5 from the ECM as a soluble species [145]. This hypothesis was supported following a cumulative mutagenesis analysis of the 201–218 region of IGFBP-5 which demonstrated a parallel loss in IGF-I and heparin binding in mutant proteins [123] (Figure 6). The loss of IGF-I affinity in the series of IGFBP-5 mutants was also reflected in the loss of their ability to inhibit the survival activity of IGF-I when added simultaneously to cultures of MCF-7 cells (M. Park, J. Shand, E. Tonner, M. Gamberoni, P. Accorsi, J. Beattie, G. J. Allan and D. J. Flint, unpublished work). The kinetics of the complexes formed between mutant IGFBPs and IGF-I were important in this respect with inhibitory activity associated with IGFBPs which formed more stable complexes as determined by lower dissociation constants. If IGFBP-5 is co-incubated with IGF-I and substratum, it enhances the activity of growth factor following addition of MCF-7 cells. Unlike the inhibitory effects of IGFBP-5, the affinity of mutants for IGF-I was not predictive of the ability of the proteins to enhance growth-factor activity. Instead, enhancing activity was related to the ability of complexes to dissociate from substratum and also the ability of IGF-I to

Figure 6   Analysis of the binding of wild-type (WT) and mutant (AA–FA) IGFBP-5 species to heparin and IGF-I was analysed by biosensor (upper panel) and blotting methodologies (lower panel)

See [123] for details of the IGFBP-5 mutants. Note the parallelism in the loss of affinity for both IGF-I and heparin with cumulative mutagenesis of positively charged residues within the region 201–218 of IGFBP-5. RU = resonance units; $e^{-2} = 10^{-2}$; molecular-mass sizes are indicated in kDa. See the text for further details. Reproduced from Endocrinology, 'Cumulative mutagenesis of the basic residues in the 201–218 region of insulin-like growth factor (IGF)-binding protein-5 results in progressive loss of both IGF-I binding and inhibition of IGF-I biological action' by G. J. Allan, E. Tonner, M. Szymanowska, J. H. Shand, S. M. Kelly, K. Phillips, R. A. Clegg, I. F. Gow, J. Beattie and D. J. Flint **147**(1), pp. 338–349, with permission. © 2006, The Endocrine Society.

dissociate from IGFBP-5 bound to substratum. Non-IGF-binding mutants did not enhance or inhibit IGF activity.

Clearly many factors will be involved in determining the distribution of IGFBP-5 between IGFs and various components of the ECM and other IGFBP-5-binding proteins. These include issues such as affinity and stability of binding complexes, local concentrations of different binding partners, conformationally allowable complex formation, proteolysis of IGFBP-5 and also the presence and concentration in the local pericellular environment of other GAG-binding IGFBPs. In addition, the activity of IGFBP-5 may depend on the nature of the ECM in the local environment [146]. Obtaining a full molecular profile at the level of the cell for all of these potential molecular complexes (especially in real time) is clearly a challenging task. Nonetheless, without this detailed information, interpretation of the observed biological effects of IGF at a cellular level may be problematic.

Although the majority of studies have examined the interaction of IGFBP-5 with GAGs or protein components of the ECM, there are reports of interaction of IGFBP-5 with other structures and proteins which are not associated with the ECM. For example, IGFBP-5 has been shown to bind the inorganic bone matrix hydroxyapatite [83]. This interaction differs from those described previously in two respects. First, the binding of IGFBP-5 to hydroxyapatite beads is a lower-affinity interaction (K_D 0.21 μM). Secondly, binding of IGFBP-5 and hydroxyapatite was actually enhanced by the peptide fragment 201–218. As indicated above, this peptide competed with the binding of IGFBP-5 to GAG and protein components of the ECM. Also somewhat unusually, the paper by Campbell and Andress [83] reported that peptide 201–218 itself bound to intact IGFBP-5 and increased its affinity for IGF-I 3-fold. This observation has not been reported in other laboratories, although the authors of this paper postulate that binding of this peptide to IGFBP-5 may be related to various anecdotal reports of the ability of IGFBP-5 to dimerize [83]. IGFBP-5 has also been reported to bind αs_2 casein micelles [137], and these structures, like hydroxyapatite, contain a high concentration of calcium phosphate. Using a yeast two-hybrid screen, IGFBP-5

has been shown to interact with the transcriptional co-activator protein FHL-2 (four-and-a-half LIM domain 2) [147], although this study did not propose a functional role for the interaction. Confirmation of this binding interaction was demonstrated when both proteins were overexpressed in the U-2 human osteosarcoma cell line and they were shown to co-localize in the cell nucleus. It remains to be seen whether the proteins interact under normal physiological conditions. Interestingly, IGFBP-5 has also been shown to localize in the nucleus of vascular smooth-muscle cells, and there is some evidence that it may possess transcriptional activity when fused to the DNA-binding domain of Gal4 [148]. Whether IGFBP-5 acts as a transcriptional co-activator along with FHL-2 remains to be determined. The yeast two-hybrid screening methodology has also demonstrated the association of IGFBP-5 and RASSF1C (isoform C of the Ras association family 1 protein group) [149]. Another study demonstrated that IGFBP-5 increased the phosphorylation status of ERK1/2 in mouse osteoblasts and also increased cell proliferation [150]. The observation that siRNA (small interfering RNA) directed towards *RASSF1C* mRNA inhibited this effect of IGFBP-5 led the authors to conclude that the effects of IGFBP-5 on ERK1/2 phosphorylation were mediated by RASSF1C [149]. This interesting area is worthy of further investigation.

IGFBP-5 AND CANCER

Mammary gland

As both IGF-I and IGF-II have well described proliferative actions in several cell types, many research groups have investigated the role of both growth factors in the aetiology and progression of various tumours. The largest body of work in this area has examined different models of mammary cancer including work in breast cancer cell lines, primary cultures and animal models of mammary cancer.

The mammary gland undergoes cycles of growth, differentiation and regression that are associated with cycles of pregnancy, lactation and involution. In this process, mammary epithelial cells

undergo cell division and differentiation to secrete milk components and are then reduced in number by the process of apoptosis at the end of lactation. As such, an examination of the regulation of this process of cell division and death in the gland under normal physiological conditions may aid in an understanding of the factors that are involved in the uncontrolled process of epithelial cell division that is characteristic of tumorigenesis. It is well established that the IGF axis plays an important role in the regulation of mammary epithelial cell function [3,151,152], and, depending on the cellular context, IGFBP-5 can have both inhibitory and enhancing effects on IGF-I activity in the gland. As has been discussed above, IGFBP-5 interacts with various ECM constituents, undergoes proteolysis and is regulated by hormones which are also important in controlling mammary gland function. These features have significance when the role of IGFBP-5 in normal and abnormal mammary epithelial cell function has been investigated. In normal mammary gland, one of the most interesting recent observations has been increased IGFBP-5 expression during the early stages of apoptosis [137,153–156]. Involution of the mammary gland can be achieved by withdrawal of pituitary hormone (GH and prolactin) support [156], by litter removal or by teat sealing the gland [155]. In each of these conditions, IGFBP-5 expression is increased within 24 h. This is before major structural changes in the gland are seen, suggesting that the protein may play an early role in cellular apoptosis and mammary gland regression. Using transgenic mice that express IGFBP-5 under the control of a β-lactoglobulin promoter, Tonner et al. [154] demonstrated that IGFBP-5 was up-regulated specifically in the mammary gland during pregnancy and lactation. Phenotypically, these animals showed abnormal mammary gland development and demonstrated reduced cellular proliferation rates and increased cell death. These differences were most apparent at parturition and early lactation, when IGFBP-5 levels increased sharply. The mammary epithelial cell has been confirmed as the location of IGFBP-5 synthesis and secretion [153,155,157], and it is postulated that the binding protein is secreted from the epithelial cell around parturition and gains access to the basal aspect of the epithelial cell surface through the leaky tight junctions which exist between the cells at this time (Figure 7). In this location, excess IGFBP-5 can neutralize IGF-I secreted by stromal cells in the tissue and thus induce apoptotic activity in the gland. In support of this theory, long R3-IGF-I (an IGF-I analogue which has low affinity for IGFBPs) partially restored lactation in transgenic animals. At approx. 48 h after parturition, tight junctions between mammary epithelial cells are less permeable, and this may be the reason for partial restoration of function in the gland of transgenic animals at this time. Furthermore, addition of IGFBP-5 to primary cultures of mouse mammary epithelial cells and to the FSK-7 mouse mammary epithelial cell line inhibits IGF-I activation of IRS-1 (IR substrate-1), protein kinase B and FKHRL-1 (forkhead in rhabdomyosarcoma-like 1), providing direct evidence for the ability of IGFBP-5 to act as an apoptotic factor by inhibiting the action of local IGF-I [153]. Although increased IGFBP-5 levels around parturition were associated with epithelial cell apoptosis, it should be noted that *IGFBP-5* mRNA is also present in epithelial cells in mid- to late pregnancy, when the cells are undergoing division and differentiation and IGFBP-5 is also secreted by these cells in culture [158]. Lactogenic hormones stimulate IGFBP-5 secretion in both the HC11 mouse mammary epithelial cell line [158a] and in primary cultures of mammary epithelial cells grown on EHS (Engelbreth–Holm–Swarm) matrix [158b]. In addition, microarray analysis of selected gene expression in virgin, pregnant, lactating and involuting mouse mammary gland indicates that IGFBP-5 expression is elevated both in mid-pregnancy and in early involution [159,160]. As indicated above, IGFBP-5 contains


Figure 7   Stromal cell derived IGF-I and epithelial cell-derived IGFBP-5 interact to regulate mammary epithelial cell function

During lactation, IGF-I maintains secretory function in the mammary epithelial cell. At this stage, the activity of the pituitary hormones GH (stimulating IGF-I secretion) and prolactin (inhibiting IGFBP-5 secretion) act to maintain a high IGF-I/IGFBP-5 ratio. During mammary gland regression and apoptosis of epithelial cells, IGFBP-5 concentrations increase and neutralize the survival factor activity of IGF-I. See the text for further details.

a progesterone-responsive element within the proximal promoter, and it has been suggested that progesterone may maintain elevated IGFBP-5 levels during pregnancy [62]. It is therefore possible that IGFBP-5 may also have a differentiating activity in the mammary gland and that the activity of the protein may depend on local IGF-I/IGFBP-5 ratios. In support of this, IGFBP-5 has been reported to have differentiation activity in other cell culture systems [24,161,162].

With this information on the potential role of IGFBP-5 in normal mammary gland apoptosis and differentiation, it is instructive to examine the work which has focused on the expression and function of the protein in mammary cancer models. These studies have used both primary cultures and breast cancer cell lines from human and rodent species. In addition, a few *in vivo* studies have been performed. Among the first tasks of early researchers was to profile the IGFBP species which were expressed in mammary tumorigenic cell lines. In contrast with the case with normal mammary epithelial cell function, this is a large body of literature, and here we discuss only the most salient observations from these data with respect to IGFBP-5. The first demonstration of the expression and secretion of IGFBP-5 by human breast cancer cell lines came in 1992 when Sheikh et al. [163] reported the presence of IGFBP-5 mRNA and protein expression in four ER (oestrogen receptor)-positive cell lines (MCF-7, T47D, ZR75 and BT474) and also in two ER-negative cell lines (Hs578T and MDA-MB-468). IGFBP-5 expression was not found in a third ER-negative cell line (MDA-MB-231). It was also reported that IGF-I increased IGFBP-5 levels (both mRNA and protein) in cultures of MCF-7 cells [164]. Enhanced IGFBP-5 expression was also evident following treatment of cells with OE_2 (oestradiol), and combined treatment with IGF-I and OE_2 resulted in a synergistic effect on IGFBP-5 expression. As IGF-I and OE_2 also had synergistic effects on cell growth, it was deemed unlikely that the induced IGFBP-5 inhibited the stimulatory activity of

IGF-I. This differs somewhat from the conclusions drawn regarding the pro-apoptotic functions of IGFBP-5 in involuting mammary gland, although no indication of the concentrations of IGFBP-5 achieved in cultures of MCF-7 cells was given. In a subsequent study, Dubois et al. [165] reported IGFBP-5 secretion by an invasive subclone of MCF-7 (MCF-7/6), whereas IGFBP-5 protein was undetectable in an non-invasive MCF-7 subclone (MCF-7/AZ). Both cell lines were ER-positive, and the differential pattern of IGFBP-5 secretion suggested that the binding protein may play a role in determining the phenotype of these subclones, although experiments designed to examine this hypothesis were not reported. IGF-I was also shown to stimulate IGFBP-5 secretion in the ER-negative cell line MDA-MB-468 [166], although there was no effect on *IGFBP-5* mRNA expression, suggesting regulation at a post-transcriptional level in this particular cell line. In support of this finding, it was shown that IGF-I regulation of IGFBP-5 levels in the T47D cell line was partly due to the ability of the growth factor to bind IGFBP-5 and protect the protein from proteolysis [78]. This phenomenon has been reported elsewhere in this review and was confirmed by the report that IGF-I analogues which had reduced affinity for IGFBP-5 had decreased ability to effect IGFBP-5 levels [78]. Treatment of T47D cells with an anti-IGF-IR blocking monoclonal antibody attenuated the effect of the growth factor, demonstrating that IGF-I also had effects which were dependent on interaction with the IGF-IR. As IGF-I did not influence the levels of *IGFBP-5* mRNA in these cells, the authors proposed that this receptor-dependent effect of IGF-I may be to regulate the expression of an IGFBP-5 protease [78]. IGF-I has also been reported to displace IGFBP-5 from ECM secreted by a mammary cell line [119] and this may be another non-receptor-mediated route by which IGF-I increases levels of soluble IGFBP-5 in cell-conditioned medium.

Of special interest was the observation that medroxyprogesterone acetate and two anti-oestrogens (RU486 and Org2058) inhibited the growth of T47D cells [167]. As these compounds decreased IGFBP-5 levels, the somewhat counterintuitive deduction was made that IGFBP-5 may act as a potential growth promoter in these cells in much the same way that IGFBP-5 has been reported to directly promote osteoblast cell growth [150]. However, subsequent reports [168–172] in which *IGFBP-5* mRNA and protein levels in MCF-7 cell cultures were increased by treatment with either anti-oestrogens or vitamin D_3-related compounds demonstrated that this alteration in the IGFBP-5 profile was associated with inhibition of cellular growth. In addition, treatment of MCF-7 cells with an IGFBP-5 antisense oligonucleotide decreased IGFBP-5 accumulation and resulted in an enhancement of basal DNA synthesis. Confirmation of the effects of vitamin D_3 were provided by the demonstration that it could reduce the level of IGF-I-stimulated tyrosine phosphorylation of the signalling intermediates IRS-1 and -2 in MCF-7 cells [170]. In addition, IGFBP-5 may sensitize breast cancer cells to the growth-inhibitory properties of other agents [173]. It appears therefore that the regulation of IGFBP-5 expression and subsequent effects on cell growth in breast cancer cells is cell-line-dependent.

IGFBP-5 mRNA and protein was also reported in breast cancer tissues and in primary cultures of breast cancer cells [174–177]. For example, Pekonen et al. [177] using RT (reverse transcription)–PCR detected *IGFBP-5* mRNA in each of 47 human breast tumour samples and reported that tumour tissue had higher levels of binding protein than the surrounding normal tissue. IGFBP-5 protein was also detected by ligand blotting in 80 breast cancer specimens [176], and the binding protein was found in the stromal compartment in the *N*-nitrosourea- and DMBA (7,12-dimethylbenz[*a*]anthracene)-induced rat mammary tumour models [174,175]. In the study by Manni et al. [175], IGFBP-5 was reported in the stromal compartment of the gland. The overwhelming body of evidence indicates that IGFBP-5 is expressed in mammary epithelial cells, and therefore the presence of IGFBP-5 in the stromal compartment may be indicative of epithelial–stromal cell communication.

It is only recently that functional studies on IGFBP-5 activity in breast cancer have been addressed. Working with the ER-negative human breast cancer cell line Hs578T, Perks et al. [178] reported that exogenously added IGFBP-5 could inhibit apoptosis induced by the ceramide analogue C2 or by the integrin-binding tripeptide RGD (Arg-Gly-Asp). As Hs578T cells do not express the IGF-IR, and as it was also demonstrated that a non-IGF-binding mutant of IGFBP-5 was able to attenuate C2-induced apoptosis in these cells, this suggested that the effects of IGFBP-5 were IGF-independent. Therefore, in this cell culture model, IGFBP-5 was viewed perhaps somewhat unusually as a survival factor. Further studies from this group [179] using inhibitors of cell signalling pathways suggested that IGFBP-5 exerted its cell-survival activity through the intracellular kinases PKC (protein kinase C) and sphingosine kinase which regulate the balance between ceramide and the survival factor sphingosine 1-phosphate [180]. McCaig et al. [179] also demonstrate that IGFBP-5 attenuates apoptosis in the IGF-responsive cell line MCF-7. However, the findings are somewhat complicated by the observation that the non-IGF-binding IGFBP-5 mutant inhibited the ability of IGF-I to confer protection against C2-induced apoptosis in this cell line, suggesting that the protective effect of IGFBP-5 was, at least in part, due to its ability to bind IGF-I. The ability of the non-IGF-binding mutant IGFBP-5 to block IGF-I survival action in MCF-7 cells was postulated to be the result of IGFBP-5-mediated disruption of the interaction between ECM components and cell-surface integrin receptors and, elsewhere in this review, we have indicated that appropriate occupancy of these receptors is required for IGF-I to exert its biological actions.

Given an excess of soluble IGFBP-5, all endogenous IGF-I would be sequestered and thus the net effect on cell survival would depend on the IGFBP-5/IGF-I ratio. In an experimental sense, it is difficult to conceive how one might differentiate between the contribution of IGFBP-5 and IGF-I to cell survival in such an IGF-I-responsive cell line. Nonetheless, these observations bear a striking similarity to the proposal of dual action of IGFBP-5 in normal mammary gland, where apoptotic function and enhancing/differentiating activity may be regulated by local IGFBP-5/IGF-I ratios.

Inhibition of growth and DNA synthesis has been observed in MDA-MB-231 and Hs578T cells transfected with IGFBP-5 and cell-cycle arrest at the G_2/M transition was also demonstrated [173]. Caspase-dependent apoptosis was described in transfected cells and IGFBP-5 has been shown to activate both caspase 8 and caspase 9 [173]. Tumours developed by injection of transfected MDA-MB-231 cells into nude mice were smaller and of lower incidence than tumours derived by injection of control vector-transfected cells. As Hs578T cells do not respond to IGF-I and as growth of MDA-MB-231 cells was not affected by a specific monoclonal antibody which blocks the activity of the IGF-IR, the effects of IGFBP-5 in the two cell lines appeared to be IGF-independent [173]. The authors demonstrated that the addition of intact or proteolytic fragments of IGFBP-5 did not affect apoptosis in these cells, indicating that the mode of action of IGFBP-5 was probably via intracrine mechanisms [173,181]. IGFBP-5 contains a classical bipartite nuclear localization signal in the 201–218 region of the protein and, in transfected cells, it was found in both nuclear and cytoplasmic compartments, although nuclear transport of IGFBP-5 was required for activity of the protein [173].

It is apparent that, for breast epithelial tumour cells, there are contradictory findings in relation to enhancing or inhibitory effects of IGFBP-5. Although some of these contradictions can be explained by features such as cell- and context-specific effects, it is clearly important that further experiments are conducted into IGFBP-5 action in breast cancer. In addition, it is clear that IGFBP-5 may exert its effects through multiple mechanisms. These mechanisms can include IGF-dependent and -independent effects. They may also be contingent on the regulation of IGFBP-5 secretion by breast cancer cells and tissue by steroid hormones and other circulating hormones and growth factors (e.g. prolactin, GH, insulin and IGF-I itself). The role of IGFBP-5 in breast cancer may be modified by proteolysis and/or the association of IGFBP-5 with the ECM and other proteins. These areas pose the most challenging tasks for future research.

Prostate

The importance of the IGF axis in prostate biology has been clearly established [182], and IGF-I has been shown to regulate the growth and division of both normal and neoplastic prostate epithelial cells [183]. These results, together with the report of a strong positive correlation between serum IGF-I levels and subsequent risk of prostate cancer [183a], has led to an examination of the role of several members of the IGF axis in benign and malignant hyperplasia of the prostate. The role of the IGF axis (principally IGFBPs) in either pharmacological- or castration-induced involution of the prostate has also been investigated. Initial studies described an increase in *IGFBP-5* mRNA expression in stromal cells derived from benign hyperplastic prostate tissue from the low levels that exist in normal prostate tissue [73]. In subsequent studies, IGFBP-5 expression was reported to be highest in stromal cell cultures derived from the trans-urethral region of the prostate gland [184]. In addition, IGFBP-5 is also expressed in the prostate cancer cell line PC-3 [186,187]. An *in situ* hybridization and immunohistochemical study of IGFBP-5 expression in benign and malignant human prostate tissue indicated an increase in IGFBP-5 protein in epithelial cells derived from malignant prostate [185]. However, *in situ* hybridization studies indicated that *IGFBP-5* mRNA expression was restricted to stromal cells, and these authors suggested that IGFBP-5 released by stromal cells may associate with epithelial cells and provide a route for intercellular communication [185]. This was analogous to the situation described in the mammary gland, although, in this tissue, IGFBP-5 expression is believed to be restricted to epithelial cells. Several studies have reported on the effects of prostate regression (achieved by castration or inhibition of testosterone 5α-reductase) on IGFBP-5 expression. Usually, IGFBP-5 expression was increased in involuting prostate, irrespective of the method by which involution was achieved [188–191] and such findings are similar to those described for the involuting mammary gland, where IGFBP-5 expression was also increased [154]. Unlike the mammary gland, however, substantial evidence for a causative role for IGFBP-5 in inducing apoptosis in prostate cells, and thus involution of the gland is largely lacking. Indeed, in some studies, it has been shown that there is a large temporal dissociation between the appearance of apoptotic cells in the involuting prostate and peak levels of IGFBP-5 expression in the tissue [191]. In addition, some immunohistochemical data indicated that IGFBP-5 did not co-stain with apoptotic cell markers in histological sections of involuting prostate [191]. Also, in contrast with studies in involuting mammary gland, expression of other IGFBPs was increased in involuting prostate [189,190]. These observations therefore cast some doubt as to the role of IGFBP-5 in apoptosis of involuting prostate.

In contrast with the involuting prostate, recent studies with prostate tumour cells have suggested a growth-enhancing effect of IGFBP-5 [192–194]. For example, stable transfection of IGFBP-5 in the prostate tumour cell line LNCaP resulted in faster growth of cells compared with vector-transfected controls [194]. Apoptosis was induced by androgen withdrawal in both transfected and untransfected cells, but IGF-I rescued only transfected cells from apoptosis [194]. This implied that IGFBP-5 in some way enhanced the anti-apoptotic action of IGF-I. In confirmation of this hypothesis, the same group demonstrated that tumours derived from LNCaP cells stably transfected with IGFBP-5 proceed more rapidly to androgen-independent growth following castration of host rats [193]. Treatment of Shionogi prostate tumour cells with antisense oligonucleotides to IGFBP-5 inhibited the growth of these cells compared with control vector-transfected cells, again implying a stimulatory effect for IGFBP-5 [193]. Such dual behaviour of IGFBP-5, i.e. up-regulated during apoptosis, but also implicated in stimulation of cellular growth and differentiation, is again reminiscent of the profile and behaviour of this protein in the mammary gland and in other tissues. Although IGFBP-5 expression is increased during apoptosis in prostate and mammary gland, an isolated report shows down-regulation of IGFBP-5 during apoptosis in rat cerebellar granule cells [195]. The overwhelming evidence, however, suggests that IGFBP-5 is up-regulated during apoptosis in cells of epithelial origin. It is somewhat disappointing that there has been little research published in the last 5 years with respect to IGFBP-5 and prostate gland function. Given the high incidence of benign and malignant hyperplasia of the prostate, it is an area that is worthy of further research.

Ovary

Ovarian granulosa cells express IGFBP-5 [196], and the expression of IGFBP-5 has also been reported in ovarian cancer cell lines [197,198]. Although the expression of IGFBP-5 is known to be associated with follicular atresia in the rat ovary [40], there are little data regarding the role of IGFBP-5 in either a growth-stimulatory or -inhibitory role in ovarian cells. One study indicated that IGFBP-5 inhibited gonadotropin-releasing hormone-stimulated growth of a human ovarian adenocarcinoma cell line, and that this effect may have been due to the sequestration of endogenously produced IGF-II [198a]. In general, however, this is a much neglected area, and further research into the role of the IGF axis in ovarian carcinomas is required.

Other cancers

Using techniques such as RT–PCR, microarray analysis, *in situ* hybridization and immunohistochemistry, the presence of IGFBP-5 in numerous tumours and cancer cell lines has been reported [67,68,199–209]. Although the pattern of IGFBP-5 expression in these cell lines varies greatly, in most tumour cells, levels of IGFBP-5 mRNA and protein were increased [207,208]. This led to the suggestion that increased levels of IGFBP-5 may either enhance the action of locally available IGF-I, leading to a stimulation of the process of tumorigenesis or, conversely, that IGFBP-5 may inhibit the action of local IGFs and attenuate tumour progression. Unfortunately, supporting experimental evidence for either of these hypotheses is largely absent in these studies. Schneider et al. [202] did report that transfection and over-expression of IGFBP-5 in mouse osteosarcoma cells resulted in a reduced basal proliferation of cells and also a reduced cellular growth response in the presence of IGF-I, suggesting both an IGF-dependent and an -independent route of action for IGFBP-5. It was also reported that addition of exogenous IGFBP-5 to

cultures of a human papilloma virus-negative cervical cancer cell line decreased the viability of the cells [210]. Conversely, the silencing of IGFBP-5 expression in two neuroblastoma cell lines using micro-RNA interference inhibited both the growth and differentiation of these cells [61]. In essence, however, a larger body of experimental work is required to establish a functional role for IGFBP-5 in the regulation of tumour cell biology.

CONCLUSIONS

There has clearly been a great deal of progress in research into the structure and function of IGFBP-5 since the protein was first cloned 14 years ago. However, there are still some large gaps in our knowledge in relation to the properties of this protein. A description of the three-dimensional structure of IGFBP-5 (and other IGFBPs) is still awaited. Achievement of this goal would help in the interpretation of IGFBP-5 activity and may go some way to explaining the complicated biological actions of the protein. Similarly, a concentrated effort needs to be made to dissect further the IGFBP-5 promoter. Relatively few transcription factors have been identified as interacting with the promoter, and it would be particularly interesting to investigate factors which might be active during cellular apoptosis. Footprinting IGFBP-5 promoter regions with nuclear extracts from cells undergoing apoptosis may prove to be a useful initial strategy. In addition, it is highly likely that other IGFBP-5 proteases will be reported in the near future. More information about the sites of proteolysis and the potential activity of proteolytic fragments would be especially useful. It is also likely that new proteins or other biomolecules which interact with IGFBP-5 will be reported. This may lead to a re-evaluation of the biological properties of the protein. In this regard, the recent demonstration of the nuclear location of IGFBP-5 and its potential to interact with other nuclear proteins is particularly interesting. In general, the mechanisms of action of IGFBP-5 also require clarification. To non-experts in the field, these can appear confusing. A distillation of some of the mechanisms proposed in this review show that IGFBP-5 may act in any one (or combination) of the following mechanisms: (i) through an IGF-independent action in IGF-null cells via regulation of the ceramide (and potentially other signalling pathways); (ii) through IGF-independent interactions with ECM–integrin-binding events acting to promote cell detachment and apoptosis; (iii) by simultaneous association with ECM and IGFs to provide a pool of growth factor in the vicinity of IGF receptors and thus enhance their activities; (iv) through an excess of soluble binding protein acting to sequester IGF-I and thus inhibit the activity of the growth factor.

Clearly such list of potential mechanisms is not exhaustive (see below), and more than one mechanism may operate at the individual cellular level at any one time. In addition, such effects are going to be influenced by the family of IGFBP-5 proteases, by the regulation of IGFBP-5 expression (e.g. by IGF-I itself) and also by the nature of the ECM in a particular cell and tissue type, by the local concentrations of each of the components in this molecular axis and also by the presence of other IGFBPs. A complete dissection of all these features in the activity of IGFBP-5 is clearly a daunting task; however, it is to be hoped that future research in each of these areas will shed further light on the properties and actions of this important protein.

REFERENCES

1   Gluckman, P., Klempt, N., Guan, J., Mallard, C., Sirimanne, E., Dragunow, M., Klempt, M., Singh, K., Williams, C. and Nikolics, K. (1992) A role for IGF-1 in the rescue of CNS neurons following hypoxic-ischemic injury. Biochem. Biophys. Res. Commun. **182**, 593–599

2   Valentinis, B. and Baserga, R. (2001) IGF-I receptor signalling in transformation and differentiation. Mol. Pathol. **54**, 133–137

3   Hadsell, D. L., Bonnette, S. G. and Lee, A. V. (2002) Genetic manipulation of the IGF-I axis to regulate mammary gland development and function. J. Dairy Sci. **85**, 365–377

4   Accili, D., Nakae, J., Kim, J. J., Park, B. C. and Rother, K. I. (1999) Targeted gene mutations define the roles of insulin and IGF-I receptors in mouse embryonic development. J. Pediatr. Endocrinol. Metab. **12**, 475–485

5   Khandwala, H. M., McCutcheon, I. E., Flyvbjerg, A. and Friend, K. E. (2000) The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr. Rev. **21**, 215–244

6   Salmon, Jr, W. D. and Daughaday, W. H. (1957) A hormonally controlled serum factor which stimulates sulfate incorporation by cartilage in vitro. J. Lab. Clin. Med. **49**, 825–836

7   Daughaday, W. H., Parker, K. A., Borowsky, S., Trivedi, B. and Kapadia, M. (1982) Measurement of somatomedin-related peptides in fetal, neonatal, and maternal rat serum by insulin-like growth factor (IGF) I radioimmunoassay, IGF-II radioreceptor assay (RRA), and multiplication-stimulating activity RRA after acid–ethanol extraction. Endocrinology **110**, 575–581

8   Rechler, M. M., Nissley, S. P., King, G. L., Moses, A. C., Van Obberghen-Schilling, E. E., Romanus, J. A., Knight, A. B., Short, P. A. and White, R. M. (1981) Multiplication stimulating activity (MSA) from the BRL 3A rat liver cell line: relation to human somatomedins and insulin. J. Supramol. Struct. Cell. Biochem. **15**, 253–286

9   Rosenfeld, R. G. and Hintz, R. L. (1980) Characterization of a specific receptor for somatomedin C (SM-C) on cultured human lymphocytes: evidence that SM-C modulates homologous receptor concentration. Endocrinology **107**, 1841–1848

10 Baxter, R. C. and Martin, J. L. (1987) Binding proteins for insulin-like growth factors in adult rat serum: comparison with other human and rat binding proteins. Biochem. Biophys. Res. Commun. **147**, 408–415

11 Binkert, C., Landwehr, J., Mary, J. L., Schwander, J. and Heinrich, G. (1989) Cloning, sequence analysis and expression of a cDNA encoding a novel insulin-like growth factor binding protein (IGFBP-2). EMBO J. **8**, 2497–2502

12 Brinkman, A., Groffen, C., Kortleve, D. J., Geurts van Kessel, A. and Drop, S. L. (1988) Isolation and characterization of a cDNA encoding the low molecular weight insulin-like growth factor binding protein (IBP-1). EMBO J. **7**, 2417–2423

13 Martin, J. L., Willetts, K. E. and Baxter, R. C. (1990) Purification and properties of a novel insulin-like growth factor-II binding protein from transformed human fibroblasts. J. Biol. Chem. **265**, 4124–4130

14 Shimasaki, S., Shimonaka, M., Zhang, H. P. and Ling, N. (1991) Identification of five different insulin-like growth factor binding proteins (IGFBPs) from adult rat serum and molecular cloning of a novel IGFBP-5 in rat and human. J. Biol. Chem. **266**, 10646–10653

15 Shimonaka, M., Schroeder, R., Shimasaki, S. and Ling, N. (1989) Identification of a novel binding protein for insulin-like growth factors in adult rat serum. Biochem. Biophys. Res. Commun. **165**, 189–195

16 Rajah, R., Katz, L., Nunn, S., Solberg, P., Beers, T. and Cohen, P. (1995) Insulin-like growth factor binding protein (IGFBP) proteases: functional regulators of cell growth. Prog. Growth Factor Res. **6**, 273–284

17 Osborne, C. K., Coronado, E. B., Kitten, L. J., Arteaga, C. I., Fuqua, S. A., Ramasharma, K., Marshall, M. and Li, C. H. (1989) Insulin-like growth factor-II (IGF-II): a potential autocrine/paracrine growth factor for human breast cancer acting via the IGF-I receptor. Mol. Endocrinol. **3**, 1701–1709

18 Scott, C. D., Martin, J. L. and Baxter, R. C. (1985) Rat hepatocyte insulin-like growth factor I and binding protein: effect of growth hormone in vitro and in vivo. Endocrinology **116**, 1102–1107

19 Melmed, S., Yamashita, S., Yamasaki, H., Fagin, J., Namba, H., Yamamoto, H., Weber, M., Morita, S., Webster, J. and Prager, D. (1996) IGF-I receptor signalling: lessons from the somatotroph. Recent Prog. Horm. Res. **51**, 189–215

20 Arai, T., Parker, A., Busby, Jr, W. and Clemmons, D. R. (1994) Heparin, heparan sulfate, and dermatan sulfate regulate formation of the insulin-like growth factor-I and insulin-like growth factor-binding protein complexes. J. Biol. Chem. **269**, 20388–20393

21 Mohan, S., Nakao, Y., Honda, Y., Landale, E., Leser, U., Dony, C., Lang, K. and Baylink, D. J. (1995) Studies on the mechanisms by which insulin-like growth factor (IGF) binding protein-4 (IGFBP-4) and IGFBP-5 modulate IGF actions in bone cells. J. Biol. Chem. **270**, 20424–20431

22 Clemmons, D. R. (2001) Use of mutagenesis to probe IGF-binding protein structure/function relationships. Endocr. Rev. **22**, 800–817

23 Firth, S. M. and Baxter, R. C. (2002) Cellular actions of the insulin-like growth factor binding proteins. Endocr. Rev. **23**, 824–854

24 Schneider, M. R., Wolf, E., Hoeflich, A. and Lahm, H. (2002) IGF-binding protein-5: flexible player in the IGF system and effector on its own. J. Endocrinol. **172**, 423–440

25 Allander, S. V., Larsson, C., Ehrenborg, E., Suwanichkul, A., Weber, G., Morris, S. L., Bajalica, S., Kiefer, M. C., Luthman, H. and Powell, D. R. (1994) Characterization of the chromosomal gene and promoter for human insulin-like growth factor binding protein-5. J. Biol. Chem. **269**, 10891–10898

26 Kou, K., Jenkins, N. A., Gilbert, D. J., Copeland, N. G. and Rotwein, P. (1994) Organization, expression, and chromosomal location of the mouse insulin-like growth factor binding protein 5 gene. Genomics **20**, 412–418

27 White, M. E., Diao, R., Hathaway, M. R., Mickelson, J. and Dayton, W. R. (1996) Molecular cloning and sequence analysis of the porcine insulin-like growth factor binding protein-5 complementary deoxyribonucleic acid. Biochem. Biophys. Res. Commun. **218**, 248–253

28 Zhu, X., Ling, N. and Shimasaki, S. (1993) Cloning of the rat insulin-like growth factor binding protein-5 gene and DNA sequence analysis of its promoter region. Biochem. Biophys. Res. Commun. **190**, 1045–1052

29 Forbes, B. E., Turner, D., Hodge, S. J., McNeil, K. A., Forsberg, G. and Wallace, J. C. (1998) Localization of an insulin-like growth factor (IGF) binding site of bovine IGF binding protein-2 using disulfide mapping and deletion mutation analysis of the C-terminal domain. J. Biol. Chem. **273**, 4647–4652

30 Hashimoto, R., Ono, M., Fujiwara, H., Higashihashi, N., Yoshida, M., Enjoh-Kimura, T. and Sakano, K. (1997) Binding sites and binding properties of binary and ternary complexes of insulin-like growth factor-II (IGF-II), IGF-binding protein-3, and acid-labile subunit. J. Biol. Chem. **272**, 27936–27942

31 Kalus, W., Zweckstetter, M., Renner, C., Sanchez, Y., Georgescu, J., Grol, M., Demuth, D., Schumacher, R., Dony, C., Lang, K. and Holak, T. A. (1998) Structure of the IGF-binding domain of the insulin-like growth factor-binding protein-5 (IGFBP-5): implications for IGF and IGF-I receptor interactions. EMBO J. **17**, 6558–6572

32 Neumann, G. M. and Bach, L. A. (1999) The N-terminal disulfide linkages of human insulin-like growth factor-binding protein-6 (hIGFBP-6) and hIGFBP-1 are different as determined by mass spectrometry. J. Biol. Chem. **274**, 14587–14594

33 Siwanowicz, I., Popowicz, G. M., Wisniewska, M., Huber, R., Kuenkele, K. P., Lang, K., Engh, R. A. and Holak, T. A. (2005) Structural basis for the regulation of insulin-like growth factors by IGF binding proteins. Structure **13**, 155–167

34 Standker, L., Braulke, T., Mark, S., Mostafavi, H., Meyer, M., Honing, S., Gimenez-Gallego, G. and Forssmann, W. G. (2000) Partial IGF affinity of circulating N- and C-terminal fragments of human insulin-like growth factor binding protein-4 (IGFBP-4) and the disulfide bonding pattern of the C-terminal IGFBP-4 domain. Biochemistry **39**, 5082–5088

35 Hodgkinson, S. C., Napier, J. R., Spencer, G. S. and Bass, J. J. (1994) Glycosaminoglycan binding characteristics of the insulin-like growth factor-binding proteins. J. Mol. Endocrinol. **13**, 105–112

36 Twigg, S. M., Kiefer, M. C., Zapf, J. and Baxter, R. C. (2000) A central domain binding site in insulin-like growth factor binding protein-5 for the acid-labile subunit. Endocrinology **141**, 454–457

37 Song, H., Shand, J. H., Beattie, J., Flint, D. J. and Allan, G. J. (2001) The carboxy-terminal domain of IGF-binding protein-5 inhibits heparin binding to a site in the central domain. J. Mol. Endocrinol. **26**, 229–239

38 Conover, C. A. and Kiefer, M. C. (1993) Regulation and biological effect of endogenous insulin-like growth factor binding protein-5 in human osteoblastic cells. J. Clin. Endocrinol. Metab. **76**, 1153–1159

39 Olney, R. C., Tsuchiya, K., Wilson, D. M., Mohtai, M., Maloney, W. J., Schurman, D. J. and Smith, R. L. (1996) Chondrocytes from osteoarthritic cartilage have increased expression of insulin-like growth factor I (IGF-I) and IGF-binding protein-3 (IGFBP-3) and -5, but not IGF-II or IGFBP-4. J. Clin. Endocrinol. Metab. **81**, 1096–1103

40 Onoda, N., Li, D., Mickey, G., Erickson, G. and Shimasaki, S. (1995) Gonadotropin-releasing hormone overcomes follicle-stimulating hormone's inhibition of insulin-like growth factor-5 synthesis and promotion of its degradation in rat granulosa cells. Mol. Cell. Endocrinol. **110**, 17–25

41 Firth, S. M. and Baxter, R. C. (1999) Characterisation of recombinant glycosylation variants of insulin-like growth factor binding protein-3. J. Endocrinol. **160**, 379–387

42 Marinaro, J. A., Neumann, G. M., Russo, V. C., Leeding, K. S. and Bach, L. A. (2000) O-glycosylation of insulin-like growth factor (IGF) binding protein-6 maintains high IGF-II binding affinity by decreasing binding to glycosaminoglycans and susceptibility to proteolysis. Eur. J. Biochem. **267**, 5378–5386

43 Hoeck, W. G. and Mukku, V. R. (1994) Identification of the major sites of phosphorylation in IGF binding protein-3. J. Cell Biochem. **56**, 262–273

44 Jones, J. I., D'Ercole, A. J., Camacho-Hubner, C. and Clemmons, D. R. (1991) Phosphorylation of insulin-like growth factor (IGF)-binding protein 1 in cell culture and in vivo: effects on affinity for IGF-I. Proc. Natl. Acad. Sci. U.S.A. **88**, 7481–7485

45 Jones, J. I., Gockerman, A. and Clemmons, D. R. (1992) Insulin-like growth factor binding protein-5 (IGFBP-5) binds to extracellular matrix and is phosphorylated. 74th Annual Endocrine Society Meeting, San Antonio, TX, U.S.A. 24–27 June, 1992, pp. 372 (abstract)

46 Imai, Y., Moralez, A., Andag, U., Clarke, J. B., Busby, Jr, W. H. and Clemmons, D. R. (2000) Substitutions for hydrophobic amino acids in the N-terminal domains of IGFBP-3 and -5 markedly reduce IGF-I binding and alter their biologic actions. J. Biol. Chem. **275**, 18188–18194

47 Shand, J. H., Beattie, J., Song, H., Phillips, K., Kelly, S. M., Flint, D. J. and Allan, G. J. (2003) Specific amino acid substitutions determine the differential contribution of the N- and C-terminal domains of insulin-like growth factor (IGF)-binding protein-5 in binding IGF-I. J. Biol. Chem. **278**, 17859–17866

48 Zeslawski, W., Beisel, H. G., Kamionka, M., Kalus, W., Engh, R. A., Huber, R., Lang, K. and Holak, T. A. (2001) The interaction of insulin-like growth factor-I with the N-terminal domain of IGFBP-5. EMBO J. **20**, 3638–3644

49 Sala, A., Capaldi, S., Campagnoli, M., Faggion, B., Labo, S., Perduca, M., Romano, A., Carrizo, M. E., Valli, M., Visai, L. et al. (2005) Structure and properties of the C-terminal domain of insulin-like growth factor-binding protein-1 isolated from human amniotic fluid. J. Biol. Chem. **280**, 29812–29819

50 Headey, S. J., Leeding, K. S., Norton, R. S. and Bach, L. A. (2004) Contributions of the N- and C-terminal domains of IGF binding protein-6 to IGF binding. J. Mol. Endocrinol. **33**, 377–386

51 Kiefer, M. C., Schmid, C., Waldvogel, M., Schlapfer, I., Futo, E., Masiarz, F. R., Green, K., Barr, P. J. and Zapf, J. (1992) Characterization of recombinant human insulin-like growth factor binding proteins 4, 5, and 6 produced in yeast. J. Biol. Chem. **267**, 12692–12699

52 Fernandez-Tornero, C., Lozano, R. M., Rivas, G., Jimenez, M. A., Standker, L., Diaz-Gonzalez, D., Forssmann, W. G., Cuevas, P., Romero, A. and Gimenez-Gallego, G. (2005) Synthesis of the blood circulating C-terminal fragment of insulin-like growth factor (IGF)-binding protein-4 in its native conformation: crystallization, heparin and IGF binding, and osteogenic activity. J. Biol. Chem. **280**, 18899–18907

53 Carrick, F. E., Hinds, M. G., McNeil, K. A., Wallace, J. C., Forbes, B. E. and Norton, R. S. (2005) Interaction of insulin-like growth factor (IGF)-I and -II with IGF binding protein-2: mapping the binding surfaces by nuclear magnetic resonance. J. Mol. Endocrinol. **34**, 685–698

54 Kou, K., Mittanck, D. W., Fu, C. and Rotwein, P. (1995) Structure and function of the mouse insulin-like growth factor binding protein 5 gene promoter. DNA Cell Biol. **14**, 241–249

55 Duan, C. and Clemmons, D. R. (1995) Transcription factor AP-2 regulates human insulin-like growth factor binding protein-5 gene expression. J. Biol. Chem. **270**, 24844–24851

56 McCarthy, T. L., Casinghino, S., Mittanck, D. W., Ji, C. H., Centrella, M. and Rotwein, P. (1996) Promoter-dependent and -independent activation of insulin-like growth factor binding protein-5 gene expression by prostaglandin E2 in primary rat osteoblasts. J. Biol. Chem. **271**, 6666–6671

57 Gabbitas, B., Pash, J. M., Delany, A. M. and Canalis, E. (1996) Cortisol inhibits the synthesis of insulin-like growth factor-binding protein-5 in bone cell cultures by transcriptional mechanisms. J. Biol. Chem. **271**, 9033–9038

58 Yeh, L. C., Adamo, M. L., Duan, C. and Lee, J. C. (1998) Osteogenic protein-1 regulates insulin-like growth factor-I (IGF-I), IGF-II, and IGF-binding protein-5 (IGFBP-5) gene expression in fetal rat calvaria cells by different mechanisms. J. Cell Physiol. **175**, 78–88

59 Ji, C., Chen, Y., Centrella, M. and McCarthy, T. L. (1999) Activation of the insulin-like growth factor-binding protein-5 promoter in osteoblasts by cooperative E box, CCAAT enhancer-binding protein, and nuclear factor-1 deoxyribonucleic acid-binding sequences. Endocrinology **140**, 4564–4572

60 Yeh, L. C. and Lee, J. C. (2000) Identification of an osteogenic protein-1 (bone morphogenetic protein-7)-responsive element in the promoter of the rat insulin-like growth factor-binding protein-5 gene. Endocrinology **141**, 3278–3286

61 Cesi, V., Giuffrida, M. L., Vitali, R., Tanno, B., Mancini, C., Calabretta, B. and Raschella, G. (2005) C/EBPα and β mimic retinoic acid activation of IGFBP-5 in neuroblastoma cells by a mechanism independent from binding to their site. Exp. Cell Res. **305**, 179–189

62 Boonyaratanakornkit, V., Strong, D. D., Mohan, S., Baylink, D. J., Beck, C. A. and Linkhart, T. A. (1999) Progesterone stimulation of human insulin-like growth factor-binding protein-5 gene transcription in human osteoblasts is mediated by a CACCC sequence in the proximal promoter. J. Biol. Chem. **274**, 26431–26438

63 Tanno, B., Negroni, A., Vitali, R., Pirozzoli, M. C., Cesi, V., Mancini, C., Calabretta, B. and Raschella, G. (2002) Expression of insulin-like growth factor-binding protein 5 in neuroblastoma cells is regulated at the transcriptional level by c-Myb and B-Myb via direct and indirect mechanisms. J. Biol. Chem. **277**, 23172–23180

64   Kulik, G., Klippel, A. and Weber, M. J. (1997) Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt. Mol. Cell. Biol. **17**, 1595–1606

65   Dong, Y. and Canalis, E. (1995) Insulin-like growth factor (IGF) I and retinoic acid induce the synthesis of IGF-binding protein 5 in rat osteoblastic cells. Endocrinology **136**, 2000–2006

66   Zhou, Y., Mohan, S., Linkhart, T. A., Baylink, D. J. and Strong, D. D. (1996) Retinoic acid regulates insulin-like growth factor-binding protein expression in human osteoblast cells. Endocrinology **137**, 975–983

67   Schmid, C., Schlapfer, I., Gosteli-Peter, M. A., Froesch, E. R. and Zapf, J. (1995) Expression, effects, and fate of IGFBP-5 are different in normal and malignant osteoblastic cells. Prog. Growth Factor Res. **6**, 167–173

68   Giudice, L. C., Irwin, J. C., Dsupin, B. A., Pannier, E. M., Jin, I. H., Vu, T. H. and Hoffman, A. R. (1993) Insulin-like growth factor (IGF), IGF binding protein (IGFBP), and IGF receptor gene expression and IGFBP synthesis in human uterine leiomyomata. Hum. Reprod. **8**, 1796–1806

69   Hossenlopp, P., Segovia, B., Lassarre, C., Roghani, M., Bredon, M. and Binoux, M. (1990) Evidence of enzymatic degradation of insulin-like growth factor-binding proteins in the 150K complex during pregnancy. J. Clin. Endocrinol. Metab. **71**, 797–805

70   Davenport, M. L., Clemmons, D. R., Miles, M. V., Camacho-Hubner, C., D'Ercole, A. J. and Underwood, L. E. (1990) Regulation of serum insulin-like growth factor-I (IGF-I) and IGF binding proteins during rat pregnancy. Endocrinology **127**, 1278–1286

71   Fielder, P. J., Thordarson, G., English, A., Rosenfeld, R. G. and Talamantes, F. (1992) Expression of a lactogen-dependent insulin-like growth factor-binding protein in cultured mouse mammary epithelial cells. Endocrinology **131**, 261–267

72   Claussen, M., Zapf, J. and Braulke, T. (1994) Proteolysis of insulin-like growth factor binding protein-5 by pregnancy serum and amniotic fluid. Endocrinology **134**, 1964–1966

73   Lee, K. O., Oh, Y., Giudice, L. C., Cohen, P., Peehl, D. M. and Rosenfeld, R. G. (1994) Identification of insulin-like growth factor-binding protein-3 (IGFBP-3) fragments and IGFBP-5 proteolytic activity in human seminal plasma: a comparison of normal and vasectomized patients. J. Clin. Endocrinol. Metab. **79**, 1367–1372

74   Camacho-Hubner, C., Busby, Jr, W. H., McCusker, R. H., Wright, G. and Clemmons, D. R. (1992) Identification of the forms of insulin-like growth factor-binding proteins produced by human fibroblasts and the mechanisms that regulate their secretion. J. Biol. Chem. **267**, 11949–11956

75   Conover, C. A. (1991) A unique receptor-independent mechanism by which insulin like growth factor I regulates the availability of insulin-like growth factor binding proteins in normal and transformed human fibroblasts. J. Clin. Invest. **88**, 1354–1361

76   Kanzaki, S., Hilliker, S., Baylink, D. J. and Mohan, S. (1994) Evidence that human bone cells in culture produce insulin-like growth factor-binding protein-4 and -5 proteases. Endocrinology **134**, 383–392

77   Conover, C. A., Baker, B. K., Bale, L. K., Clarkson, J. T., Liu, F. and Hintz, R. L. (1993) Human hepatoma cells synthesize and secrete insulin-like growth factor Ia prohormone under growth hormone control. Regul. Pept. **48**, 1–8

78   Shemer, J., Yaron, A., Werner, H., Shao, Z. M., Sheikh, M. S., Fontana, J. A., LeRoith, D. and Roberts, Jr, C. T. (1993) Regulation of insulin-like growth factor (IGF) binding protein-5 in the T47D human breast carcinoma cell line by IGF-I and retinoic acid. J. Clin. Endocrinol. Metab. **77**, 1246–1250

79   Arai, T., Arai, A., Busby, Jr, W. H. and Clemmons, D. R. (1994) Glycosaminoglycans inhibit degradation of insulin-like growth factor-binding protein-5. Endocrinology **135**, 2358–2363

80   Fowlkes, J. L., Thrailkill, K. M., George-Nascimento, C., Rosenberg, C. K. and Serra, D. M. (1997) Heparin-binding, highly basic regions within the thyroglobulin type-1 repeat of insulin-like growth factor (IGF)-binding proteins (IGFBPs) -3, -5, and -6 inhibit IGFBP-4 degradation. Endocrinology **138**, 2280–2285

81   Matsumoto, T., Tsurumoto, T., Goldring, M. B. and Shindo, H. (2000) Differential effects of IGF-binding proteins, IGFBP-3 and IGFBP-5, on IGF-I action and binding to cell membranes of immortalized human chondrocytes. J. Endocrinol. **166**, 29–37

82   Sunic, D., McNeil, J. D., Andress, D. L. and Belford, D. A. (1998) Insulin-like growth factor binding protein-5 proteolytic activity in ovine articular chondrocyte culture. Biochim. Biophys. Acta **1425**, 567–576

83   Campbell, P. G. and Andress, D. L. (1997) Insulin-like growth factor (IGF)-binding protein-5-(201–218) region regulates hydroxyapatite and IGF-I binding. Am. J. Physiol. **273**, E1005–E1013

84   Zheng, B., Clarke, J. B., Busby, W. H., Duan, C. and Clemmons, D. R. (1998) Insulin-like growth factor-binding protein-5 is cleaved by physiological concentrations of thrombin. Endocrinology **139**, 1708–1714

85   Gibson, T. L. and Cohen, P. (1999) Inflammation-related neutrophil proteases, cathepsin G and elastase, function as insulin-like growth factor binding protein proteases. Growth Horm. IGF Res. **9**, 241–253

86   Loechel, F., Fox, J. W., Murphy, G., Albrechtsen, R. and Wewer, U. M. (2000) ADAM 12-S cleaves IGFBP-3 and IGFBP-5 and is inhibited by TIMP-3. Biochem. Biophys. Res. Commun. **278**, 511–515

87   Mohan, S., Thompson, G. R., Amaar, Y. G., Hathaway, G., Tschesche, H. and Baylink, D. J. (2002) ADAM-9 is an insulin-like growth factor binding protein-5 protease produced and secreted by human osteoblasts. Biochemistry **41**, 15394–15403

88   Busby, Jr, W. H., Nam, T. J., Moralez, A., Smith, C., Jennings, M. and Clemmons, D. R. (2000) The complement component C1s is the protease that accounts for cleavage of insulin-like growth factor-binding protein-5 in fibroblast medium. J. Biol. Chem. **275**, 37638–37644

89   Byun, D., Mohan, S., Yoo, M., Sexton, C., Baylink, D. J. and Qin, X. (2001) Pregnancy-associated plasma protein-A accounts for the insulin-like growth factor (IGF)-binding protein-4 (IGFBP-4) proteolytic activity in human pregnancy serum and enhances the mitogenic activity of IGF by degrading IGFBP-4 in vitro. J. Clin. Endocrinol. Metab. **86**, 847–854

90   Laursen, L. S., Overgaard, M. T., Soe, R., Boldt, H. B., Sottrup-Jensen, L., Giudice, L. C., Conover, C. A. and Oxvig, C. (2001) Pregnancy-associated plasma protein-A (PAPP-A) cleaves insulin-like growth factor binding protein (IGFBP)-5 independent of IGF: implications for the mechanism of IGFBP-4 proteolysis by PAPP-A. FEBS Lett. **504**, 36–40

91   Overgaard, M. T., Boldt, H. B., Laursen, L. S., Sottrup-Jensen, L., Conover, C. A. and Oxvig, C. (2001) Pregnancy-associated plasma protein-A2 (PAPP-A2), a novel insulin-like growth factor-binding protein-5 proteinase. J. Biol. Chem. **276**, 21849–21853

92   Soe, R., Overgaard, M. T., Thomsen, A. R., Laursen, L. S., Olsen, I. M., Sottrup-Jensen, L., Haaning, J., Giudice, L. C., Conover, C. A. and Oxvig, C. (2002) Expression of recombinant murine pregnancy-associated plasma protein-A (PAPP-A) and a novel variant (PAPP-Ai) with differential proteolytic activity. Eur. J. Biochem. **269**, 2247–2256

93   Hou, J., Clemmons, D. R. and Smeekens, S. (2005) Expression and characterization of a serine protease that preferentially cleaves insulin-like growth factor binding protein-5. J. Cell. Biochem. **94**, 470–484

94   Jones, J. I., Gockerman, A., Busby, Jr, W. H., Camacho-Hubner, C. and Clemmons, D. R. (1993) Extracellular matrix contains insulin-like growth factor binding protein-5: potentiation of the effects of IGF-I. J. Cell Biol. **121**, 679–687

95   Imai, Y., Busby, Jr, W. H., Smith, C. E., Clarke, J. B., Garmong, A. J., Horwitz, G. D., Rees, C. and Clemmons, D. R. (1997) Protease-resistant form of insulin-like growth factor-binding protein 5 is an inhibitor of insulin-like growth factor-I actions on porcine smooth muscle cells in culture. J. Clin. Invest. **100**, 2596–2605

96   Kiepe, D., Andress, D. L., Mohan, S., Standker, L., Ulinski, T., Himmele, R., Mehls, O. and Tonshoff, B. (2001) Intact IGF-binding protein-4 and -5 and their respective fragments isolated from chronic renal failure serum differentially modulate IGF-I actions in cultured growth plate chondrocytes. J. Am. Soc. Nephrol. **12**, 2400–2410

97   Kuemmerle, J. F. and Zhou, H. (2002) Insulin-like growth factor-binding protein-5 (IGFBP-5) stimulates growth and IGF-I secretion in human intestinal smooth muscle by Ras-dependent activation of p38 MAP kinase and Erk1/2 pathways. J. Biol. Chem. **277**, 20563–20571

98   Andress, D. L. (1995) Heparin modulates the binding of insulin-like growth factor (IGF) binding protein-5 to a membrane protein in osteoblastic cells. J. Biol. Chem. **270**, 28289–28296

99   Sunic, D., McNeil, J. D., Rayner, T. E., Andress, D. L. and Belford, D. A. (1998) Regulation of insulin-like growth factor-binding protein-5 by insulin-like growth factor I and interleukin-1α in ovine articular chondrocytes. Endocrinology **139**, 2356–2362

100 Booth, B. A., Boes, M., Dake, B. L., Caldwell, E. E., Weiler, J. M. and Bar, R. S. (2000) Effect of IGFBP-derived peptides on incorporation of ^{35}SO$_4$ into proteoglycans. Growth Horm. IGF Res. **10**, 224–229

101 Berfield, A. K., Andress, D. L. and Abrass, C. K. (2000) IGFBP-5(201–218) stimulates Cdc42GAP aggregation and filopodia formation in migrating mesangial cells. Kidney Int. **57**, 1991–2003

102 Parker, A., Rees, C., Clarke, J., Busby, Jr, W. H. and Clemmons, D. R. (1998) Binding of insulin-like growth factor (IGF)-binding protein-5 to smooth-muscle cell extracellular matrix is a major determinant of the cellular response to IGF-I. Mol. Biol. Cell **9**, 2383–2392

103 Standker, L., Wobst, P., Mark, S. and Forssmann, W. G. (1998) Isolation and characterization of circulating 13-kDa C-terminal fragments of human insulin-like growth factor binding protein-5. FEBS Lett. **441**, 281–286

104 Durant, D., Pereira, R., Stadmeyer, L. and Canalis, E. (2004) Transgenic mice expressing selected insulin-like growth factor-binding protein-5 fragments do not exhibit enhanced bone formation. Growth Horm. IGF Res. **14**, 319–327

105   Atti, E., Boskey, A. L. and Canalis, E. (2005) Overexpression of IGF-binding protein 5 alters mineral and matrix properties in mouse femora: an infrared imaging study. Calcif. Tissue Int. **76**, 187–193

106   Devlin, R. D., Du, Z., Buccilli, V., Jorgetti, V. and Canalis, E. (2002) Transgenic mice overexpressing insulin-like growth factor binding protein-5 display transiently decreased osteoblastic function and osteopenia. Endocrinology **143**, 3955–3962

107   Durant, D., Pereira, R. M. and Canalis, E. (2004) Overexpression of insulin-like growth factor binding protein-5 decreases osteoblastic function in vitro. Bone **35**, 1256–1262

108   Salih, D. A., Mohan, S., Kasukawa, Y., Tripathi, G., Lovett, F. A., Anderson, N. F., Carter, E. J., Wergedal, J. E., Baylink, D. J. and Pell, J. M. (2005) Insulin-like growth factor-binding protein-5 induces a gender-related decrease in bone mineral density in transgenic mice. Endocrinology **146**, 931–940

109   Salih, D. A., Tripathi, G., Holding, C., Szestak, T. A., Gonzalez, M. I., Carter, E. J., Cobb, L. J., Eisemann, J. E. and Pell, J. M. (2004) Insulin-like growth factor-binding protein 5 (Igfbp5) compromises survival, growth, muscle development, and fertility in mice. Proc. Natl. Acad. Sci. U.S.A. **101**, 4314–4319

110   Clemmons, D. R., Busby, Jr, W. H., Garmong, A., Schultz, D. R., Howell, D. S., Altman, R. D. and Karr, R. (2002) Inhibition of insulin-like growth factor binding protein 5 proteolysis in articular cartilage and joint fluid results in enhanced concentrations of insulin-like growth factor 1 and is associated with improved osteoarthritis. Arthritis Rheum. **46**, 694–703

111   Iwanaga, H., Matsumoto, T., Enomoto, H., Okano, K., Hishikawa, Y., Shindo, H. and Koji, T. (2005) Enhanced expression of insulin-like growth factor-binding proteins in human osteoarthritic cartilage detected by immunohistochemistry and in situ hybridization. Osteoarthritis Cartilage **13**, 439–448

112   Sharp, C. A., Brown, S. J., Davie, M. W., Magnusson, P. and Mohan, S. (2004) Increased matrix concentrations of IGFBP-5 in cancellous bone in osteoarthritis. Ann. Rheum. Dis. **63**, 1162–1165

113   Bunn, R. C. and Fowlkes, J. L. (2003) Insulin-like growth factor binding protein proteolysis. Trends Endocrinol. Metab. **14**, 176–181

114   Clemmons, D. R., Underwood, L. E., Chatelain, P. G. and Van Wyk, J. J. (1983) Liberation of immunoreactive somatomedin-C from its binding proteins by proteolytic enzymes and heparin. J. Clin. Endocrinol. Metab. **56**, 384–389

115   Hakeda, Y., Kawaguchi, H., Hurley, M., Pilbeam, C. C., Abreu, C., Linkhart, T. A., Mohan, S., Kumegawa, M. and Raisz, L. G. (1996) Intact insulin-like growth factor binding protein-5 (IGFBP-5) associates with bone matrix and the soluble fragments of IGFBP-5 accumulated in culture medium of neonatal mouse calvariae by parathyroid hormone and prostaglandin E_2-treatment. J. Cell Physiol. **166**, 370–379

116   Chen, Y., Shu, H., Ji, C., Casinghino, S., Kim, K., Gundberg, C. M., Centrella, M. and McCarthy, T. L. (1998) Insulin-like growth factor binding proteins localize to discrete cell culture compartments in periosteal and osteoblast cultures from fetal rat bone. J. Cell. Biochem. **71**, 351–362

117   Monget, P., Pisselet, C. and Monniaux, D. (1998) Expression of insulin-like growth factor binding protein-5 by ovine granulosa cells is regulated by cell density and programmed cell death in vitro. J. Cell. Physiol. **177**, 13–25

118   Ingman, W. V., Owens, P. C. and Armstrong, D. T. (2000) Differential regulation by FSH and IGF-I of extracellular matrix IGFBP in bovine granulosa cells: effect of association with the oocyte. Mol. Cell. Endocrinol. **164**, 53–58

119   Oosterlaken-Dijksterhuis, M. A., Kwant, M. M., Slob, A., Hellmen, E. and Mol, J. A. (1999) IGF-I and retinoic acid regulate the distribution pattern of IGFBPs synthesized by the canine mammary tumor cell line CMT-U335. Breast Cancer Res. Treat. **54**, 11–23

120   Zheng, B. and Clemmons, D. R. (2000) Methods for preparing extracellular matrix and quantifying insulin-like growth factor-binding protein binding to the ECM. Methods Mol. Biol. **139**, 221–230

121   Abrass, C. K., Berfield, A. K. and Andress, D. L. (1997) Heparin binding domain of insulin-like growth factor binding protein-5 stimulates mesangial cell migration. Am. J. Physiol. **273**, F899–F906

122   Booth, B. A., Boes, M., Andress, D. L., Dake, B. L., Kiefer, M. C., Maack, C., Linhardt, R. J., Bar, K., Caldwell, E. E., Weiler, J. et al. (1995) IGFBP-3 and IGFBP-5 association with endothelial cells: role of C-terminal heparin binding domain. Growth Regul. **5**, 1–17

123   Allan, G. J., Tonner, E., Szymanowska, M., Shand, J. H., Kelly, S. M., Phillips, K., Clegg, R. A., Gow, I. F., Beattie, J. and Flint, D. J. (2006) Cumulative mutagenesis of the basic residues in the 201–218 region of insulin-like growth factor binding protein (IGFBP)-5 results in progressive loss of both IGF-I binding and inhibition of IGF-I biological action. Endocrinology **147**, 338–349

124   Arai, T., Busby, Jr, W. and Clemmons, D. R. (1996) Binding of insulin-like growth factor (IGF) I or II to IGF-binding protein-2 enables it to bind to heparin and extracellular matrix. Endocrinology **137**, 4571–4575

124a Nam, T. J., Busby, Jr, W. H., Rees, C. and Clemmons, D. R. (2000) Thrombospondin and osteopontin bind to insulin-like growth factor (IGF)-binding protein-5 leading to an alteration in IGF-I-stimulated cell growth. Endocrinology **141**, 1100–1106

125   Moralez, A. M., Maile, L. A., Clarke, J., Busby, Jr, W. H. and Clemmons, D. R. (2005) Insulin-like growth factor binding protein-5 (IGFBP-5) interacts with thrombospondin-1 to induce negative regulatory effects on IGF-I actions. J. Cell. Physiol. **203**, 328–334

126   Nam, T., Moralez, A. and Clemmons, D. (2002) Vitronectin binding to IGF binding protein-5 (IGFBP-5) alters IGFBP-5 modulation of IGF-I actions. Endocrinology **143**, 30–36

127   Kanatani, M., Sugimoto, T., Nishiyama, K. and Chihara, K. (2000) Stimulatory effect of insulin-like growth factor binding protein-5 on mouse osteoclast formation and osteoclastic bone-resorbing activity. J. Bone Miner. Res. **15**, 902–910

128   Miyakoshi, N., Richman, C., Kasukawa, Y., Linkhart, T. A., Baylink, D. J. and Mohan, S. (2001) Evidence that IGF-binding protein-5 functions as a growth factor. J. Clin. Invest. **107**, 73–81

129   Richman, C., Baylink, D. J., Lang, K., Dony, C. and Mohan, S. (1999) Recombinant human insulin-like growth factor-binding protein-5 stimulates bone formation parameters in vitro and in vivo. Endocrinology **140**, 4699–4705

130   Twigg, S. M. and Baxter, R. C. (1998) Insulin-like growth factor (IGF)-binding protein 5 forms an alternative ternary complex with IGFs and the acid-labile subunit. J. Biol. Chem. **273**, 6074–6079

131   Kricker, J. A., Towne, C. L., Firth, S. M., Herington, A. C. and Upton, Z. (2003) Structural and functional evidence for the interaction of insulin-like growth factors (IGFs) and IGF binding proteins with vitronectin. Endocrinology **144**, 2807–2015

132   Hyde, C., Hollier, B., Anderson, A., Harkin, D. and Upton, Z. (2004) Insulin-like growth factors (IGF) and IGF-binding proteins bound to vitronectin enhance keratinocyte protein synthesis and migration. J. Invest. Dermatol. **122**, 1198–1206

133   Maile, L. A., Imai, Y., Clarke, J. B. and Clemmons, D. R. (2002) Insulin-like growth factor I increases $\alpha v \beta 3$ affinity by increasing the amount of integrin-associated protein that is associated with non-raft domains of the cellular membrane. J. Biol. Chem. **277**, 1800–1805

134   Nichols, T. C., du Laney, T., Zheng, B., Bellinger, D. A., Nickols, G. A., Engleman, W. and Clemmons, D. R. (1999) Reduction in atherosclerotic lesion size in pigs by $\alpha v \beta 3$ inhibitors is associated with inhibition of insulin-like growth factor-I-mediated signaling. Circ. Res. **85**, 1040–1045

135   Nam, T. J., Busby, Jr, W. and Clemmons, D. R. (1997) Insulin-like growth factor binding protein-5 binds to plasminogen activator inhibitor-I. Endocrinology **138**, 2972–2978

136   Arai, T., Clarke, J., Parker, A., Busby, Jr, W., Nam, T. and Clemmons, D. R. (1996) Substitution of specific amino acids in insulin-like growth factor (IGF) binding protein 5 alters heparin binding and its change in affinity for IGF-I response to heparin. J. Biol. Chem. **271**, 6099–6106

137   Flint, D. J., Tonner, E. and Allan, G. J. (2000) Insulin-like growth factor binding proteins: IGF-dependent and -independent effects in the mammary gland. J. Mammary Gland Biol. Neoplasia **5**, 65–73

138   Hahnefeld, C., Drewianka, S. and Herberg, F. W. (2004) Determination of kinetic data using surface plasmon resonance biosensors. Methods Mol. Med. **94**, 299–320

139   Wu, S. J. and Chaiken, I. (2004) Biosensor analysis of receptor-ligand interactions. Methods Mol. Biol. **249**, 93–110

140   Robinson, S. A. and Rosenzweig, S. A. (2004) Synthesis and characterization of biotinylated forms of insulin-like growth factor-1: topographical evaluation of the IGF-1/IGF-2 and IGFBP-3 interface. Biochemistry **43**, 11533–11545

141   Yan, X., Forbes, B. E., McNeil, K. A., Baxter, R. C. and Firth, S. M. (2004) Role of N- and C-terminal residues of insulin-like growth factor (IGF) binding protein-3 in regulating IGF complex formation and receptor activation. J. Biol. Chem. **279**, 53232–53240

141a Beattie, J., Phillips, K., Shand, J. H., Szymanowska, M., Flint, D. J. and Allan, G. J. (2005) Molecular recognition characteristics in the insulin-like growth factor (IGF)-insulin-like growth factor binding protein-3/5 (IGFBP-3/5) heparin axis. J. Mol. Endocrinol. **34**, 163–175

142   Martin, J. L., Ballesteros, M. and Baxter, R. C. (1992) Insulin-like growth factor-I (IGF-I) and transforming growth factor-β1 release IGF-binding protein-3 from human fibroblasts by different mechanisms. Endocrinology **131**, 1703–1710

143   Allan, G. J., Zannoni, A., McKinnell, I., Otto, W. R., Holzenberger, M., Flint, D. J. and Patel, K. (2003) Major components of the insulin-like growth factor axis are expressed early in chicken embryogenesis, with IGF binding protein (IGFBP)-5 expression subject to regulation by Sonic Hedgehog. Anat. Embryol. **207**, 73–84

144   Bramani, S., Song, H., Beattie, J., Tonner, E., Flint, D. J. and Allan, G. J. (1999) Amino acids within the extracellular matrix (ECM) binding region (201–218) of rat insulin-like growth factor binding protein (IGFBP)-5 are important determinants in binding IGF-I. J. Mol. Endocrinol. **23**, 117–123

145   Song, H., Beattie, J., Campbell, I. W. and Allan, G. J. (2000) Overlap of IGF- and heparin-binding sites in rat IGF-binding protein-5. J. Mol. Endocrinol. **24**, 43–51

146   Zheng, B., Duan, C. and Clemmons, D. R. (1998) The effect of extracellular matrix proteins on porcine smooth muscle cell insulin-like growth factor (IGF) binding protein-5 synthesis and responsiveness to IGF-I. J. Biol. Chem. **273**, 8994–9000

147   Amaar, Y. G., Thompson, G. R., Linkhart, T. A., Chen, S. T., Baylink, D. J. and Mohan, S. (2002) Insulin-like growth factor-binding protein 5 (IGFBP-5) interacts with a four and a half LIM protein 2 (FHL2). J. Biol. Chem. **277**, 12053–12060

148   Xu, Q., Li, S., Zhao, Y., Maures, T. J., Yin, P. and Duan, C. (2004) Evidence that IGF binding protein-5 functions as a ligand-independent transcriptional regulator in vascular smooth muscle cells. Circ. Res. **94**, E46–E54

149   Amaar, Y. G., Baylink, D. J. and Mohan, S. (2005) Ras-association domain family 1 protein, RASSF1C, is an IGFBP-5 binding partner and a potential regulator of osteoblast cell proliferation. J. Bone Miner. Res. **20**, 1430–1439

150   Andress, D. L. and Birnbaum, R. S. (1992) Human osteoblast-derived insulin-like growth factor (IGF) binding protein-5 stimulates osteoblast mitogenesis and potentiates IGF action. J. Biol. Chem. **267**, 22467–22472

151   Neuenschwander, S., Schwartz, A., Wood, T. L., Roberts, Jr, C. T., Henninghausen, L. and LeRoith, D. (1996) Involution of the lactating mammary gland is inhibited by the IGF system in a transgenic mouse model. J. Clin. Invest. **97**, 2225–2232

152   Ruan, W. and Kleinberg, D. L. (1999) Insulin-like growth factor I is essential for terminal end bud formation and ductal morphogenesis during mammary development. Endocrinology **140**, 5075–5081

153   Marshman, E., Green, K. A., Flint, D. J., White, A., Streuli, C. H. and Westwood, M. (2003) Insulin-like growth factor binding protein 5 and apoptosis in mammary epithelial cells. J. Cell Sci. **116**, 675–682

154   Tonner, E., Barber, M. C., Allan, G. J., Beattie, J., Webster, J., Whitelaw, C. B. and Flint, D. J. (2002) Insulin-like growth factor binding protein-5 (IGFBP-5) induces premature cell death in the mammary glands of transgenic mice. Development **129**, 4547–4557

155   Tonner, E., Barber, M. C., Travers, M. T., Logan, A. and Flint, D. J. (1997) Hormonal control of insulin-like growth factor-binding protein-5 production in the involuting mammary gland of the rat. Endocrinology **138**, 5101–5107

156   Tonner, E., Quarrie, L., Travers, M., Barber, M., Logan, A., Wilde, C. and Flint, D. (1995) Does an IGF-binding protein (IGFBP) present in involuting rat mammary gland regulate apoptosis? Prog. Growth Factor Res. **6**, 409–414

157   Allar, M. A. and Wood, T. L. (2004) Expression of the insulin-like growth factor binding proteins during postnatal development of the murine mammary gland. Endocrinology **145**, 2467–2477

158   Wood, T. L., Richert, M. M., Stull, M. A. and Allar, M. A. (2000) The insulin-like growth factors (IGFs) and IGF binding proteins in postnatal development of murine mammary glands. J. Mammary Gland Biol. Neoplasia **5**, 31–42

158a   Phillips, K., Park, A. M., Quamie, L. H., Boutinaud, M., Flint, D. J. and Beattie, J. (2003) Regulation of IGFBP-5 and -2 during differentiation of the HC11 mouse mammary epithelial cell line. J. Mol. Endocrinol. **31**, 197–208

158b   Lochrie, J. D., Phillips, K., Tonner, E., Flint, D. J., Allan, G. J., Price, N. C. and Beattie, J. (2006) Insulin-like growth factor binding protein (IGFBP)-5 is upregulated during both differentiation and apoptosis in primary cultures of mouse mammary epithelial cells. J. Cell. Physiol., doi:10.1002/jcp.20587

159   Clarkson, R. W. and Watson, C. J. (2003) Microarray analysis of the involution switch. J. Mammary Gland Biol. Neoplasia **8**, 309–319

160   Rudolph, M. C., McManaman, J. L., Hunter, L., Phang, T. and Neville, M. C. (2003) Functional development of the mammary gland: use of expression profiling and trajectory clustering to reveal changes in gene expression during pregnancy, lactation, and involution. J. Mammary Gland Biol. Neoplasia **8**, 287–307

161   Cheng, H. L., Shy, M. and Feldman, E. L. (1999) Regulation of insulin-like growth factor-binding protein-5 expression during Schwann cell differentiation. Endocrinology **140**, 4478–4485

162   Rotwein, P., James, P. L. and Kou, K. (1995) Rapid activation of insulin-like growth factor binding protein-5 gene transcription during myoblast differentiation. Mol. Endocrinol. **9**, 913–923

163   Sheikh, M. S., Shao, Z. M., Clemmons, D. R., LeRoith, D., Roberts, Jr, C. T. and Fontana, J. A. (1992) Identification of the insulin-like growth factor binding proteins 5 and 6 (IGFBP-5 and 6) in human breast cancer cells. Biochem. Biophys. Res. Commun. **183**, 1003–1010

164   McGuire, Jr, W. L., Jackson, J. G., Figueroa, J. A., Shimasaki, S., Powell, D. R. and Yee, D. (1992) Regulation of insulin-like growth factor-binding protein (IGFBP) expression by breast cancer cells: use of IGFBP-1 as an inhibitor of insulin-like growth factor action. J. Natl. Cancer Inst. **84**, 1336–1341

165   Dubois, V., Couissi, D., Schonne, E., Remacle, C. and Trouet, A. (1995) Intracellular levels and secretion of insulin-like-growth-factor-binding proteins in MCF-7/6, MCF-7/AZ and MDA-MB-231 breast cancer cells: differential modulation by estrogens in serum-free medium. Eur. J. Biochem. **232**, 47–53

166   Sheikh, M. S., Shao, Z. M., Hussain, A., Clemmons, D. R., Chen, J. C., Roberts, Jr, C. T., LeRoith, D. and Fontana, J. A. (1993) Regulation of insulin-like growth factor-binding-protein-1, 2, 3, 4, 5, and 6: synthesis, secretion, and gene expression in estrogen receptor-negative human breast carcinoma cells. J. Cell. Physiol. **155**, 556–567

167   Coutts, A., Murphy, L. J. and Murphy, L. C. (1994) Expression of insulin-like growth factor binding proteins by T-47D human breast cancer cells: regulation by progestins and antiestrogens. Breast Cancer Res. Treat. **32**, 153–164

168   Huynh, H., Yang, X. F. and Pollak, M. (1996) A role for insulin-like growth factor binding protein 5 in the antiproliferative action of the antiestrogen ICI 182780. Cell Growth Differ. **7**, 1501–1506

169   Parisot, J. P., Leeding, K. S., Hu, X. F., DeLuise, M., Zalcberg, J. R. and Bach, L. A. (1999) Induction of insulin-like growth factor binding protein expression by ICI 182,780 in a tamoxifen-resistant human breast cancer cell line. Breast Cancer Res. Treat. **55**, 231–242

170   Rozen, F. and Pollak, M. (1999) Inhibition of insulin-like growth factor I receptor signaling by the vitamin D analogue EB1089 in MCF-7 breast cancer cells: a role for insulin-like growth factor binding proteins. Int. J. Oncol. **15**, 589–594

171   Rozen, F., Yang, X. F., Huynh, H. and Pollak, M. (1997) Antiproliferative action of vitamin D-related compounds and insulin-like growth factor-binding protein 5 accumulation. J. Natl. Cancer Inst. **89**, 652–656

172   Swami, S., Raghavachari, N., Muller, U. R., Bao, Y. P. and Feldman, D. (2003) Vitamin D growth inhibition of breast cancer cells: gene expression patterns assessed by cDNA microarray. Breast Cancer Res. Treat. **80**, 49–62

173   Butt, A. J., Dickson, K. A., Jambazov, S. and Baxter, R. C. (2005) Enhancement of tumor necrosis factor-α-induced growth inhibition by insulin-like growth factor-binding protein-5 (IGFBP-5), but not IGFBP-3 in human breast cancer cells. Endocrinology **146**, 3113–3122

174   Huynh, H. (1998) *In vivo* regulation of the insulin-like growth factor system of mitogens by human chorionic gonadotropin. Int. J. Oncol. **13**, 571–557

175   Manni, A., Badger, B., Wei, L., Zaenglein, A., Grove, R., Khin, S., Heitjan, D., Shimasaki, S. and Ling, N. (1994) Hormonal regulation of insulin-like growth factor II and insulin-like growth factor binding protein expression by breast cancer cells *in vivo*: evidence for stromal epithelial interactions. Cancer Res. **54**, 2934–2942

176   McGuire, S. E., Hilsenbeck, S. G., Figueroa, J. A., Jackson, J. G. and Yee, D. (1994) Detection of insulin-like growth factor binding proteins (IGFBPs) by ligand blotting in breast cancer tissues. Cancer Lett. **77**, 25–32

177   Pekonen, F., Nyman, T., Ilvesmaki, V. and Partanen, S. (1992) Insulin-like growth factor binding proteins in human breast cancer tissue. Cancer Res. **52**, 5204–5207

178   Perks, C. M., Bowen, S., Gill, Z. P., Newcomb, P. V. and Holly, J. M. (1999) Differential IGF-independent effects of insulin-like growth factor binding proteins (1–6) on apoptosis of breast epithelial cells. J. Cell. Biochem. **75**, 652–664

179   McCaig, C., Perks, C. M. and Holly, J. M. (2002) Intrinsic actions of IGFBP-3 and IGFBP-5 on Hs578T breast cancer epithelial cells: inhibition or accentuation of attachment and survival is dependent upon the presence of fibronectin. J. Cell. Sci. **115**, 4293–4303

180   Mathias, S., Pena, L. A. and Kolesnick, R. N. (1998) Signal transduction of stress via ceramide. Biochem. J. **335**, 465–480

181   Schedlich, L. J., Young, T. F., Firth, S. M. and Baxter, R. C. (1998) Insulin-like growth factor-binding protein (IGFBP)-3 and IGFBP-5 share a common nuclear transport pathway in T47D human breast carcinoma cells. J. Biol. Chem. **273**, 18347–18352

182   Peehl, D. M., Cohen, P. and Rosenfeld, R. G. (1996) The role of insulin-like growth factors in prostate biology. J. Androl. **17**, 2–4

183   Cohen, P., Peehl, D. M., Lamson, G. and Rosenfeld, R. G. (1991) Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins in primary cultures of prostate epithelial cells. J. Clin. Endocrinol. Metab. **73**, 401–407

183a   Li, L., Yu, H., Schumacher, F., Casey, G. and Witte, J. S. (2003) Relation of serum insulin-like growth factor I (IGF-I) and IGF binding protein-3 to risk of prostate cancer (United States). Cancer Causes Control **14**, 721–726

184   Boudon, C., Rodier, G., Lechevallier, E., Mottet, N., Barenton, B. and Sultan, C. (1996) Secretion of insulin-like growth factors and their binding proteins by human normal and hyperplastic prostatic cells in primary culture. J. Clin. Endocrinol. Metab. **81**, 612–617

185   Tennant, M. K., Thrasher, J. B., Twomey, P. A., Birnbaum, R. S. and Plymate, S. R. (1996) Insulin-like growth factor-binding proteins (IGFBP)-4, -5, and -6 in the benign and malignant human prostate: IGFBP-5 messenger ribonucleic acid localization differs from IGFBP-5 protein localization. J. Clin. Endocrinol. Metab. **81**, 3783–3792

186   Conover, C. A., Perry, J. E. and Tindall, D. J. (1995) Endogenous cathepsin D-mediated hydrolysis of insulin-like growth factor-binding proteins in cultured human prostatic carcinoma cells. J. Clin. Endocrinol. Metab. **80**, 987–993

187 Kimura, G., Kasuya, J., Giannini, S., Honda, Y., Mohan, S., Kawachi, M., Akimoto, M. and Fujita-Yamaguchi, Y. (1996) Insulin-like growth factor (IGF) system components in human prostatic cancer cell-lines: LNCaP, DU145, and PC-3 cells. Int. J. Urol. **3**, 39–46

188 Guenette, R. S. and Tenniswood, M. (1994) The role of growth factors in the suppression of active cell death in the prostate: an hypothesis. Biochem. Cell Biol. **72**, 553–559

189 Nickerson, T. and Huynh, H. (1999) Vitamin D analogue EB1089-induced prostate regression is associated with increased gene expression of insulin-like growth factor binding proteins. J. Endocrinol. **160**, 223–229

190 Nickerson, T., Pollak, M. and Huynh, H. (1998) Castration-induced apoptosis in the rat ventral prostate is associated with increased expression of genes encoding insulin-like growth factor binding proteins 2, 3, 4 and 5. Endocrinology **139**, 807–810

191 Thomas, L. N., Cohen, P., Douglas, R. C., Lazier, C. and Rittmaster, R. S. (1998) Insulin-like growth factor binding protein 5 is associated with involution of the ventral prostate in castrated and finasteride-treated rats. Prostate **35**, 273–278

192 Gleave, M. E. and Miyake, H. (2000) Castration-induced upregulation of insulin-like growth factor binding protein-5 potentiates IGF-1 and accelerates androgen-independent progression in prostate cancer. Prostate Cancer Prostatic Dis. **3**, S16

193 Miyake, H., Nelson, C., Rennie, P. S. and Gleave, M. E. (2000) Overexpression of insulin-like growth factor binding protein-5 helps accelerate progression to androgen-independence in the human prostate LNCaP tumor model through activation of phosphatidylinositol 3′-kinase pathway. Endocrinology **141**, 2257–2265

194 Miyake, H., Pollak, M. and Gleave, M. E. (2000) Castration-induced up-regulation of insulin-like growth factor binding protein-5 potentiates insulin-like growth factor-I activity and accelerates progression to androgen independence in prostate cancer models. Cancer Res. **60**, 3058–3064

195 Roschier, M., Kuusisto, E., Suuronen, T., Korhonen, P., Kyrylenko, S. and Salminen, A. (2001) Insulin-like growth factor binding protein 5 and type-1 insulin-like growth factor receptor are differentially regulated during apoptosis in cerebellar granule cells. J. Neurochem. **76**, 11–20

196 Adashi, E. Y., Resnick, C. E., Hernandez, E. R., Hurwitz, A. and Rosenfeld, R. G. (1990) Ovarian granulosa cell-derived insulin-like growth factor (IGF) binding proteins: release of low molecular weight, high-affinity IGF-selective species. Mol. Cell. Endocrinol. **74**, 175–184

197 Hofmann, J., Wegmann, B., Hackenberg, R., Kunzmann, R., Schulz, K. D. and Havemann, K. (1994) Production of insulin-like growth factor binding proteins by human ovarian carcinoma cells. J. Cancer Res. Clin. Oncol. **120**, 137–142

198 Krywicki, R. F., Figueroa, J. A., Jackson, J. G., Kozelsky, T. W., Shimasaki, S., Von Hoff, D. D. and Yee, D. (1993) Regulation of insulin-like growth factor binding proteins in ovarian cancer cells by oestrogen. Eur. J. Cancer **29A**, 2015–2019

198a Ho, M. N., Delgado, C. H., Owens, G. A. and Steller, M. A. (1997) Insulin-like growth factor-II participates in the biphasic effect of a gonadotropin releasing hormone agonist on ovarian cancer cell growth. Fertil. Steril. **67**, 870–876

199 Drescher, B., Lauke, H., Hartmann, M., Davidoff, M. S. and Zumkeller, W. (1997) Immunohistochemical pattern of insulin-like growth factor (IGF) I, IGF II and IGF binding proteins 1 to 6 in carcinoma *in situ* of the testis. Mol. Pathol. **50**, 298–303

200 Cheung, C., Vesey, D., Cotterill, A., Douglas, M., Gobe, G., Nicol, D. and Johnson, D. (2005) Altered messenger RNA and protein expressions for insulin-like growth factor family members in clear cell and papillary renal cell carcinomas. Int. J. Urol. **12**, 17–28

201 Gong, Y., Ballejo, G., Alkhalaf, B., Molnar, P., Murphy, L. C. and Murphy, L. J. (1992) Phorbol esters differentially regulate the expression of insulin-like growth factor-binding proteins in endometrial carcinoma cells. Endocrinology **131**, 2747–2754

202 Schneider, M. R., Zhou, R., Hoeflich, A., Krebs, O., Schmidt, J., Mohan, S., Wolf, E. and Lahm, H. (2001) Insulin-like growth factor-binding protein-5 inhibits growth and induces differentiation of mouse osteosarcoma cells. Biochem. Biophys. Res. Commun. **288**, 435–442

203 Stolf, B. S., Carvalho, A. F., Martins, W. K., Runza, F. B., Brun, M., Hirata, Jr, R., Jordao Neves, E., Soares, F. A., Postigo-Dias, J., Kowalski, L. P. and Reis, L. F. (2003) Differential expression of IGFBP-5 and two human ESTs in thyroid glands with goiter, adenoma and papillary or follicular carcinomas. Cancer Lett. **191**, 193–202

204 Takahashi, M., Papavero, V., Yuhas, J., Kort, E., Kanayama, H. O., Kagawa, S., Baxter, R. C., Yang, X. J., Gray, S. G. and Teh, B. T. (2005) Altered expression of members of the IGF-axis in clear cell renal cell carcinoma. Int. J. Oncol. **26**, 923–931

205 Vorwerk, P., Wex, H., Hohmann, B., Mohnike, K., Schmidt, U. and Mittler, U. (2002) Expression of components of the IGF signalling system in childhood acute lymphoblastic leukaemia. Mol. Pathol. **55**, 40–45

206 Wegmann, B. R., Schoneberger, H. J., Kiefer, P. E., Jaques, G., Brandscheid, D. and Havemann, K. (1993) Molecular cloning of IGFBP-5 from SCLC cell lines and expression of IGFBP-4, IGFBP-5 and IGFBP-6 in lung cancer cell lines and primary tumours. Eur. J. Cancer **29A**, 1578–1584

207 Wulbrand, U., Remmert, G., Zofel, P., Wied, M., Arnold, R. and Fehmann, H. C. (2000) mRNA expression patterns of insulin-like growth factor system components in human neuroendocrine tumours. Eur. J. Clin. Invest. **30**, 729–739

208 Yi, H. K., Hwang, P. H., Yang, D. H., Kang, C. W. and Lee, D. Y. (2001) Expression of the insulin-like growth factors (IGFs) and the IGF-binding proteins (IGFBPs) in human gastric cancer cells. Eur. J. Cancer **37**, 2257–2263

209 Zumkeller, W., Muller, D., Muller, S., Gunther, C. and Westphal, M. (1998) Expression and synthesis of insulin-like growth factor-binding proteins in human glioma cell lines. Int. J. Oncol. **12**, 129–135

210 Higo, H., Duan, C., Clemmons, D. R. and Herman, B. (1997) Retinoic acid inhibits cell growth in HPV negative cervical carcinoma cells by induction of insulin-like growth factor binding protein-5 (IGFBP-5) secretion. Biochem. Biophys. Res. Commun. **239**, 706–709

211 Jones, J. I., Gockerman, A., Busby, Jr, W. H., Wright, G. and Clemmons, D. R. (1993) Insulin-like growth factor binding protein 1 stimulates cell migration and binds to the $\alpha 5\beta 1$ integrin by means of its Arg-Gly-Asp sequence. Proc. Natl. Acad. Sci. U.S.A. **90**, 10553–10557

212 Oh, Y., Muller, H. L., Pham, H. and Rosenfeld, R. G. (1993) Demonstration of receptors for insulin-like growth factor binding protein-3 on Hs578T human breast cancer cells. J. Biol. Chem. **268**, 26045–26048